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General remarks 
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General remarks 
Introduction 
Gastroparesis is a condition characterized by delayed gastric emptying, which is caused by an 
abnormality of gastrointestinal motility. In diabetic patients, although delayed gastric emptying 
was once considered a rare sequela, it is now recognized as an important clinical complication. 
Delayed gastric emptying occurs in approximately 30-50% in long-standing Type 1 and Type 2 
diabetic patients (Horowitz et al., 2002) and causes upper gastrointestinal symptoms (discomfort, 
frequent vomiting, anorexia, emaciation and so on) that decrease patients’ quality of life (Talley, 
1995; Vandenplas et al., 2004). Furthermore, delayed gastric emptying affects postprandial 
glycemic excursions because it impairs the delivery of nutrients to the small intestine. 
Autonomic neuropathy induced by long-standing hyperglycemia is considered a major cause of 
delayed gastric emptying in diabetic patients (Ziegler et al., 1996), although reversible delayed 
gastric emptying can be induced by acute hyperglycemia (fasting plasma glucose > ~300mg/dL) 
in healthy subjects and Type 1 patients (Cucchiara et al., 1998; Fraser et al., 1990; Oster-
Jorgensen et al., 1990). Patients with clear symptomatic delayed gastric emptying are diagnosed 
as having diabetic gastroparesis. Therefore, a drug treatment for delayed gastric emptying has 
been sought (Horowitz et al., 2002). 
Drugs for treating the above symptoms are termed gastroprokinetic agents (Scarpignato, 1996). 
These drugs stimulate gastric motility, reducing the delay in gastric emptying and thus 
improving the symptoms. The prokinetic agents can be classified into two main groups on the 
basis of their mechanisms of action, namely, serotonin agonists such as cisapride, and dopamine 
antagonists such as metoclopramide and domperidone. These drugs have been used to treat 
patients with diabetic gastroparesis. However, dopamine antagonists often give poor symptom 
response because their prokinetic effects are only moderate (Tally, 1995). In addition, they have 
a risk of causing extrapyramidal reactions and hyperprolactinemia (Bateman et al., 1989; 
Brogden et al., 1982; Tonini et al., 2004), so cisapride became the most widely used prokinetic 
agent. Cisapride improved delayed gastric emptying and symptoms in patients with 
gastroparesis (Fraser et al., 1994; Vandenplas et al., 2004). Because cisapride has also been 
reported to have a potential risk of causing fatal arrhythmia in humans (Wysowski et al., 2001), 
it has been withdrawn from the market in many countries. Therefore, novel treatments are 
needed for this disease. 
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In 1984, it was discovered that erythromycin, a macrolide antibiotic, mimics the effect of 
motilin and induces phase III contractions which start in the stomach (Itoh et al., 1984). It has 
been well known that motilin, a linear 22-amino acid polypeptide (Brown et al., 1971, 1973), is 
periodically released in the interdigestive state and that this release is associated with phase III 
activity of the migrating motor complex (MMC) (Figure 0-1; Itoh et al., 1983). 
 
Figure 0-1 MMC pattern in the 
canine gastrointestinal tract and 
cyclic pattern of plasma motilin 
levels.  
During the interdigestive state, the plasma 
motilin concentration fluctuates at about 100-
min intervals and each peak of the motilin 
concentration coincides with the end of band of 
strong contractions (phase III activity) in the 
gastric antrum. Reprinted from Itoh et al., 
(1983).  
Further pharmacology studies have shown that erythromycin and other 14-member macrolides 
exhibit a motilin-like effect on the gastrointestinal tract, both in in vivo and in in vitro conditions 
(Itoh, 1997; Peeters, 2006) via motilin receptors, since erythromycin can displace 125I-labeled 
motilin bound to the receptor (Peeters et al., 1989; Hasler et al., 1992). Janssens et al. (1990) 
demonstrated that orally administered erythromycin was associated with improved gastric 
emptying in patients with diabetic gastroparesis. In a comparative meta-analysis it was found 
that erythromycin was a stronger prokinetic agent than the existing drugs, such as domperidone, 
metoclopramide and cisapride (Sturm et al., 1999). However, the antibiotic activity of 
erythromycin makes its long-term use in patients undesirable. The other disadvantage shared by 
erythromycin and most of its derivatives is that they rapidly degrade in the acidic conditions, 
making oral administration poor effective. Therefore, even more potent erythromycin 
derivatives, with the advantages of being orally active and devoid of antibacterial activity, 
seemed to be good candidates for relieving gastroparesis. Mitemcinal (GM-611; erythromycin, 
8,9-didehydro-N-demethyl-9-deoxo-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-
11-oxo-,(2E)-2-butenedioate (2:1); Figure 0-2) was the product of these efforts.  
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Figure 0-2  Chemical structures of erythromycin A (molecular weight is 733.93) 
(A) and mitemcinal (molecular weight is 814.02) (B). The chemical structural 
differences of mitemcinal from that of erythromycin are surrounded by circles. 
 
So far, mitemcinal has shown potent and selective motilin receptor agonist activity and excellent 
acid-resistance in vitro (Koga et al., 1994; Takanashi et al., 2007). In vivo, oral mitemcinal has 
stimulated gastrointestinal motility in conscious dogs in a motilin-like manner (Ozaki et al., 
2007B), and clinically, it accelerated delayed gastric emptying and improved symptoms in 
patients with idiopathic and diabetic gastroparesis, while causing few adverse reactions (Fang et 
al., 2004; Kipnes et al., 2004; McCallum et al., 2006). The aim of this work, therefore, was to 
find the evidence to suggest whether or not mitemcinal may have the potential to replace 
cisapride as the treatment of choice for delayed gastric emptying.  
 
Summary of this study 
In order to assess the possibility that mitemcinal is likely to be useful for the treatment of 
patients with gastroparesis, the effects of orally administered mitemcinal on normal and 
experimentally-induced delayed gastric emptying were firstly investigated in conscious dogs. 
Cisapride was tested in parallel with mitemcinal so that their efficacies could be compared 
(ChapterⅠ).  
 
Although delayed gastric emptying has been observed in many established rodent diabetic 
models (James et al., 2004; Liu et al., 2004), these models are not useful for the investigation of 
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mitemcinal’s effects because the gastrointestinal tract of rodents is insensitive to motilin 
agonists (Strunz et al., 1975). There was a need for a new diabetic model in an animal whose 
gastrointestinal tract is sensitive to motilin agonists. The model also needed to be long lived, 
with stable moderate hyperglycemia, to maximize the chance of the animal developing delayed 
gastric emptying and to minimize the occurrence of reversible delayed gastric emptying due to 
marked acute hyperglycemia. Therefore, diabetic dogs that showed a stable moderate 
hyperglycemia were obtained by injection of a mixture of streptozotocin and alloxan, and kept 
until developing delayed gastric emptying. In the canine model of diabetic gastroparesis, the 
effects of orally administered mitemcinal on delayed gastric emptying were assessed and those 
of cisapride were compared (ChapterⅡ).  
 
The pig is very valuable for biomedical research because the anatomy and physiology of the 
cardiovascular and digestive systems of pigs and humans are similar (Miller et al., 1987; 
Swindle et al., 1986). The streptozotocin-induced diabetic pigs have been widely used to 
investigate endocrinology and metabolism in diabetes (Grussner et al., 1993; Koopmans et al., 
2006). After injection of streptozotocin, Göttingen minipigs that showed a stable moderate 
hyperglycemia were selcted like as a canine model of diabetes. They were kept until developing 
delayed gastric emptying so that the effects of orally administered mitemcinal on delayed gastric 
emptying and postprandial glucose were studied (ChapterⅢ). 
 
There are several differences in the actions of motilin in different species, especially between 
humans, rabbits and dogs (Itoh, 1997). Our previous study demonstrated that the response of 
Rhesus monkeys to motilin and motilin agonists were quite similar to those in humans, both in 
vitro and in vivo (Yogo et al., 2007). In order to investigate whether mitemcinal would likely to 
have the potential to take the place of cisapride, we assessed the effects of mitemcinal on gastric 
emptying in conscious Rhesus monleys and compared those of erythromycin, EM-574 and 
cisapride (ChapterⅣ).  
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1. Oral mitemcinal (GM-611), an erythromycin-derived prokinetic, 
accelerates normal and experimentally delayed gastric 
emptying in conscious dogs 
1.1 Introduction 
Gastroparesis is a condition characterised by delayed gastric emptying, which is caused by 
impaired gastrointestinal motility. Gastroparesis can cause upper gastrointestinal symptoms 
(discomfort, frequent vomiting, anorexia, etc.), decreasing the quality of life (Vandenplas et al., 
2004). Therefore, several prokinetic drugs have been used to treat patients with gastroparesis; in 
particular metoclopramide, domperidone and cisapride (Vandenplas et al., 2004). Of these, 
metoclopramide and domperidone often give poor symptom response because their prokinetic 
effects are only moderate (Talley, 1995) and they sometimes cause extrapyramidal reactions and 
hyperprolactinemia (Tonini et al., 2004), so cisapride, a 5-hydroxytryptamine(5-HT)4 receptor 
agonist, became the most widely used prokinetic drug. Cisapride showed effectiveness at 
accelerating gastric emptying in normal subjects (Duan et al., 1995) and at improving delayed 
gastric emptying in patients with gastroparesis (Vandenplas et al., 2004; Fraser et al., 1994). 
Although widely accepted as an effective treatment for gastroparesis, cisapride has been 
withdrawn from the market in many countries because of cardiovascular side-effects in humans 
(prolonged QT/QTc intervals and torsades de pointes in humans) (Wysowski et al., 2001). 
Therefore, novel treatments for gastroparesis are needed to take the place of cisapride. 
Erythromycin, a macrolide antibiotic, has also been used to treat gastroparetic patients 
(Vandenplas et al., 2004) because, as a motilin receptor agonist, it stimulates gastrointestinal 
motility (Itoh et al., 1984; Peeters, 1993). To overcome the disadvantages of erythromycin, 
several erythromycin derivatives with no antimicrobial activity and enhanced motilin-like 
activity have been produced with the aim of treating patients with idiopathic, diabetic, 
postoperative or chemotherapy induced gastroparesis. Examples of such derivatives include 
EM-523 (Ōmura et al., 1987), EM-574 (Tsuzuki et al., 1989) and ABT-229 (Li et al., 2004). 
However, one disadvantage shared by most erythromycin derivatives is that they rapidly 
degrade in the acidic environment of the stomach (Koga et al., 1994), making oral 
administration problematic. 
The drug investigated in the present study is a new erythromycin-derived motilin agonist, 
mitemcinal (GM-611) (Koga et al., 1994). In vitro studies have demonstrated that mitemcinal is 
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a potent and selective motilin receptor agonist with excellent acid resistance (Koga et al., 1994; 
Takanashi et al., 2007). Orally administered mitemcinal has been shown to stimulate 
gastrointestinal motility in a motilin-like manner in conscious dogs (Ozaki et al., 2007B). 
Clinical trials of mitemcinal have clearly demonstrated that orally administered mitemcinal can 
improved delayed gastric emptying in patients with idiopathic and diabetic gastroparesis with 
minimal side-effects (Fang et al., 2004; Kipnes et al., 2004). 
With the aim of finding further evidence that mitemcinal is likely to be useful for the treatment 
of patients with gastroparesis, the present study investigated the effects of orally administered 
mitemcinal on gastric emptying and gastrointestinal motility in conscious normal dogs, as well 
as in conscious gastroparetic dogs in which gastric emptying was experimentally delayed by 
administration of clonidine or by vagotomy. Because the main need in the treatment of 
gastroparesis is for a safe replacement for cisapride, cisapride was tested in parallel with 
mitemcinal so that their efficacies could be compared. 
 
1.2 Materials and methods 
1.2.1 Materials 
Mitemcinal was synthesized in the organic laboratory of Chugai Pharmaceutical Co. Ltd 
(Shizuoka, Japan). Cisapride was extracted from Risamol® fine granules (Mitsubishi Pharma, 
Osaka, Japan). The structure and high quality (>99% pure by HPLC) of the extracted cisapride 
powder used were confirmed by instrumental analyses ([1H]-nuclear magnetic resonance, mass 
spectroscopy and elemental analysis). Both drugs were suspended in 3% gum arabic solution 
(the corresponding vehicle). Clonidine was prepared by dissolving clonidine hydrochloride 
(Sigma-Aldrich Japan, Tokyo, Japan) in 0.9% saline (the corresponding vehicle). The test meal 
for investigation of gastric emptying was 195 g canned dog food (Pedigree Chum; 85 kcal/100 
g; Master Foods, Tokyo, Japan) thoroughly mixed with 30 mg paracetamol (AAP; Wako Pure 
Chemical, Osaka, Japan) per kg bodyweight (referred to below as the ‘test meal’). 
 
1.2.2 Animals 
Forty-four beagle/CSK dogs of either sex (8-10 kg; obtained from Chugai Research Institute for 
Medical Science, Shizuoka, Japan) were used in the present study. These dogs were used for 
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experiments performed in normal dogs, dogs administered clonidine and in vagotomised dogs. 
A total of 29 (15, five and nine) dogs was used to investigate gastric emptying and a total of 15 
(11, two and two) dogs was used to investigate antroduodenal motility (in normal dogs, 
clonidine-treated dogs and vagotomised dogs, respectively). All animal procedures were 
conducted in accordance with Chugai Pharmaceutical’s Guide for the Care and Use of 
Laboratory Animals and all experimental protocols were approved by the Institutional Animal 
Care and Use Committee. All surgical procedures were performed under general anesthesia 
induced with 30-35 mg/kg i.v., pentobarbital sodium (Nembutal®; Abbott Laboratories, Chicago, 
IL, USA) after overnight fasting. 
 
1.2.3 Preparation 
The dogs used in gastric emptying experiments were prepared by inserting a silicone tube (602-
205; Dow Corning, Midland, MI, USA) into the superior vena cava through a branch of the 
external jugular vein for blood sampling and inserting a silicone gastric tube via a small incision 
into the body of the stomach at a predefined site for drug administration. The other ends of these 
tubes were passed under the skin, brought out between the scapulae and secured firmly with silk 
sutures. To minimise artifactual influences on gastric emptying, force transducers were not 
implanted in these animals. 
The dogs used in antroduodenal motility experiments were prepared by opening the abdominal 
cavity and suturing force transducers (F-12IS; Star Medical, Tokyo, Japan) onto the serosa of the 
gastrointestinal tract at the gastric antrum and the duodenum (3 cm proximal and distal from the 
pyloric ring, respectively) in an orientation that made it possible to measure circular muscle 
contractions (Inatomi et al., 1989). The lead wires from the force transducers were brought out 
through a stab wound in the abdominal wall, passed under the skin, brought out between the 
scapulae and secured firmly with silk sutures. For drug administration, a silicone gastric tube 
was inserted into the stomach and brought out between the scapulae, as above, and then secured 
at the same place as the lead wires. The intraperitoneal cavity was then sterilized and the 
abdominal wound was closed up.  
After surgery, all dogs were placed in jackets (Takasaki Gishi, Gunma, Japan) to protect the 
silicone tubes and lead wires. The dogs were allowed 2-3 weeks to recover before the 
subsequent experiments were started. 
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1.2.4 Measurement of gastric emptying and motility 
Gastric emptying was assessed by the paracetamol method (Heading et al., 1973), as follows. 
Dogs prepared for investigation of gastric emptying were fasted overnight and then fed a test 
meal. Venous blood samples were withdrawn from the blood sampling tube every 15 min up to 
120 min after the test meal and plasma was immediately separated from the blood by 
centrifugation at 15000 g for 5 min at 4℃. The plasma AAP concentration was measured by 
HPLC. The following variables were calculated as indices of gastric emptying: peak plasma 
AAP concentration (Cmax), plasma AAP concentration at 45 min (C45) and area under the AAP 
concentration-time curve up to 60 min after feeding (AUC0-60).  
Motility was assessed by processing the signals from the force transducers implanted in dogs 
prepared for investigation of motility. For qualitative analysis, signals were passed through Itoh-
type amplifiers (SS-1786; Nihon Kohden, Tokyo, Japan) and recorded on thermal pen recorders 
(WR3701; Graphtec, Tokyo, Japan). For quantitative analysis (normal dogs only), the antral 
signal was fed into a personal computer and the antral motility index (MI) was calculated from 
the area between the contractile wave and the baseline. For the interdigestive state, the 
maximum antral contraction relative to baseline during spontaneous migrating motor complex 
(MMC) phase III was found, the hypothetical MI if this maximum contraction were to last for 1 
min was calculated and the antral MI values were expressed as percentages of this (Inatomi et 
al., 1989). For the digestive state, the integrated antral MI up to 60 min after administration 
(antral MI0-60) was calculated (Ozaki et al., 2007B). 
 
1.2.5 Establishment of gastroparesis models 
To establish the clonidine-treated model, dogs prepared for use in gastric emptying experiments 
were injected with clonidine hydrochloride (0.01, 0.03 or 0.1 mg/kg) or vehicle (0.9% saline) 
subcutaneously in the back of the neck immediately after a test meal (n=5). Clonidine dose-
dependently decreased the postprandial AAP concentration (i.e. it decreased gastric emptying). 
It was judged that the minimum effective dose of clonidine was 0.03 mg/kg (see Results), so 
injection of 0.03 mg/kg of clonidine in the above manner was established as the procedure for 
inducing delayed gastric emptying in clonidine-treated dogs. 
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To establish the vagotomised model, 2 weeks after assessing prevagotomy baseline gastric 
emptying in nine dogs and motility in two dogs prepared as above, we performed thoracotomy 
at the eighth intercostal space under artificial respiration, cut the anterior and posterior vagal 
trunks and rami communicantes around the esophagus above the diaphragm (taking care to not 
to damage surrounding organs) and then closed the chest. After confirming that all 11 
vagotomised dogs exhibited delayed gastric emptying and inhibited motility 2 weeks after 
vagotomy, we studied the effects of mitemcinal and cisapride in these dogs. After all 
experiments had been completed, we confirmed the completeness of truncal vagotomy in all 
animals by macroscopic examination at autopsy. 
 
1.2.6 Experiments 
In normal dogs, gastric emptying was studied by administering mitemcinal (0.25, 0.5 or 1 
mg/kg; n=10) or cisapride (1, 3 or 10 mg/kg; n=5) 15 min before a test meal. Motility in the 
interdigestive state was studied by administering mitemcinal (0.0003, 0.001, 0.003, 0.01 or 0.03 
mg/kg) or cisapride (0.1, 0.3, 1 or 3 mg/kg) 15 min after cessation of phase III MMC activity in 
the gastric antrum (n=5) and motility in the digestive state was studied by administering 
mitemcinal (0.3, 1 or 3 mg/kg) or cisapride (3, 10 or 30 mg/kg) 2 h after feeding (n=6) (Ozaki et 
al., 2007B). 
In clonidine-treated dogs, gastric emptying was studied by administering mitemcinal (0.25, 0.5 
or 1 mg/kg) or cisapride (1, 3 or 10 mg/kg) 15 min before a test meal. Clonidine (0.03 mg/kg) 
was injected subcutaneously immediately after the test meal (n=5). Motility after feeding was 
studied qualitatively by administering mitemcinal (1 mg/kg) or cisapride (3 mg/kg) 15 min 
before feeding and clonidine immediately after feeding (n=2).  
In vagotomised dogs, gastric emptying was studied by administering mitemcinal (0.125, 0.25 or 
0.5 mg/kg) or cisapride (3 mg/kg) 15 min before the test meal (n=9). Motility was studied in the 
interdigestive and digestive states with no drugs administered and in the digestive state by 
administering mitemcinal (0.25 mg/kg) or cisapride (3 mg/kg) 15 min before feeding (n=2). 
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1.2.7 Statistical analysis 
All data are expressed as the mean ± SEM. Dunnett’s multiple comparison test was used to 
compare the response to mitemcinal, clonidine and cisapride with the response to their controls 
and a two-tailed paired t-test was used to compare gastric emptying after clonidine and control 
treatments and to compare gastric emptying before and after vagotomy. SAS version 8.2 (SAS 
Institute Japan, Tokyo, Japan) was used for the analyses. Differences were considered 
significant if P<0.05. 
 
1.3 Results 
1.3.1 Normal dogs 
1.3.1.1 Gastric emptying 
Oral administration of mitemcinal (0.25, 0.5 or 1 mg/kg) 15 min before a test meal changed the 
time-course of the postprandial plasma AAP concentration in normal dogs (Figure 1-1A), 
significantly increasing all three indices of gastric emptying (Cmax, C45 and AUC0-60 of AAP) at 
doses of 0.5 and 1 mg/kg (Figure 1-2). Cisapride (1, 3 or 10 mg/kg), administered in the same 
way, had no effect at any dose (Figures 1-1B, 1-2). These results indicate that mitemcinal 
accelerated gastric emptying in conscious normal dogs, whereas cisapride did not. 
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Figure 1-1  Postprandial plasma paracetamol (AAP) in conscious dogs given (A) 
0.25 (○), 0.5 (△) and 1 mg/kg (□) mitemcinal or (B) 1 (○), 3 (△) and 10 mg/kg 
(□) cisapride p.o. 15 min before test meal. (●), vehicle (3% gum arabic). Data are 
the mean ± SEM of 10 (A) or five (B) dogs. 
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Figure 1-2  Indices of gastric emptying in dogs given mitemcinal or cisapride. (A) 
Peak plasma paracetamol (AAP) concentration (Cmax), (B) plasma AAP 
concentration at 45 min (C45) and (C) area under the AAP concentration-time 
curve up to 60 min after feeding (AUC0-60). Vehicle: 3% gum Arabic. Data are the 
mean ± SEM of 10 (mitemcinal) or five (cisapride) dogs. *P < 0.05 compared with 
vehicle (Dunnett’s test). 
 
1.3.1.2 Interdigestive motility 
Oral administration of mitemcinal (0.001, 0.003, 0.01 or 0.03 mg/kg) and cisapride (1 or 3 
mg/kg) 15 min after cessation of spontaneous phase III activity in the gastric antrum induced 
MMC-like antral and duodenal contractions in a dose-dependent manner, but the doses of 
cisapride required to induce similar effects were approximately 100-fold higher (Figures 1-3A, 
1-3C, 1-4A). The level of contractile activity after administration of 0.001 mg/kg mitemcinal 
(mean antral MI = 224.3 ± 58.7 from five dogs) was similar to the spontaneous MMC phase III 
contractions seen regularly before administration (mean antral MI = 244.3 ± 12.2, from 100 
observations in five dogs; dashed line in Figure 1-4A). 
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Figure 1-3  Typical tracings of contractile activity in dogs given (A) 0.003 and (B) 
1mg/kg mitemcinal or (C) 1 and (D) 10 mg/kg cisapride. GA, gastric antrum; D, 
duodenum. 
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Figure 1-4  Dose-response curve for antral motility to mitemcinal (○ ) and 
cisapride (●) in dogs. (A) Test drugs given 15 min after the end of spontaneous 
phaseⅢ. Dashed line: antral motility index (MI) in spontaneous phaseⅢ. (B) Test 
drugs given 2 h after feeding. The horizontal dashed line indicates the integrated 
MI up to 60 min after dosing (MI0-60) for the vehicle (SEM = 21.6). Data are the 
mean ± SEM of five (A) or six (B) dogs. 
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1.3.1.3 Digestive motility 
During the digestive state (low-amplitude contractions, no motor quiescence, no MMC activity), 
oral administration of mitemcinal (1 or 3 mg/kg) increased the amplitude of antral and duodenal 
contractions (Figure 1-3B) and increased antral MI0-60 in a dose-dependent manner (Figure 1-4 
B). Cisapride (3, 10 or 30 mg/kg) administered in the same way gave mixed results with no 
clear trend (Figures 1-3D, 1-4B). Doses of cisapride higher than 30 mg/kg were not 
administered because 30 mg/kg cisapride induces an adverse central nervous system effect 
(sedation). 
 
1.3.2 Clonidine-treated dogs 
1.3.2.1 Establishment of the clonidine-treated model 
The time-courses of postprandial plasma AAP concentration induced by clonidine (0.01, 0.03 or 
0.1 mg/kg) or vehicle (0.9% saline) injected subcutaneously immediately after the test meal in 
conscious dogs is shown in Figure 1-5. Clonidine dose-dependently decreased peak plasma AAP 
and increased the time to peak plasma AAP, indicating that clonidine induced delayed gastric 
emptying in a dose-dependent manner. We judged the minimum effective dose of clonidine in 
dogs to be 0.03 mg/kg (Figure 1-5), so we established the following experimental protocol for 
clonidine treatment: 0.03 mg/kg clonidine was administered subcutaneously immediately after a 
test meal to induce delayed gastric emptying.  
 
 
Figure 1-5  Postprandial plasma paraceta-
mol (AAP) in conscious dogs injected with 
clonidine immediately after a test meal. (●), 
vehicle (0.9% saline); ( ○ ), 0.01mg/kg 
clonidine; (△), 0.03 mg/kg clonidine; (□), 
0.1 mg/kg clonidine. Data are the mean ± 
SEM of five dogs. 
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1.3.2.2 Gastric emptying 
Clonidine (0.03 mg/kg) administered subcutaneously immediately after a test meal decreased all 
three indices of gastric emptying and the decreases in C45 and AUC0-60 were significant (Figure 
1-6). Oral administration of mitemcinal (0.25, 0.5 or 1 mg/kg) 15 min before the test meal dose-
dependently reversed these decreases and the increases in C45 and AUC0-60 were significant at 
the highest dose (1 mg/kg; Figure 1-6). Cisapride (1, 3 or 10 mg/kg) administered in the same 
way showed a tendency to improve the decreases in indices induced by clonidine, but the 
increases were not significant and the dose-response curve tended to be bell-shaped (Figure 1-6). 
These results indicate that mitemcinal overcame the delayed gastric emptying in clonidine-
treated dogs, whereas cisapride only caused a slight tendency towards reversal that was not dose 
dependent. 
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Figure 1-6  Indices of gastric emptying in dogs given only clonidine (CLO; s.c. 
immediately after a test meal) and in dogs given mitemcinal or cisapride (p.o. 
15min before the test meal) followed by clonidine. (A) Peak plasma paracetamol 
(AAP) concentration (Cmax), (B) plasma AAP concentration at 45 min (C45) and (C) 
area under the AAP concentration-time curve up to 60 min after feeding (AUC0-60). 
Sal, vehicle for clonidine (0.9% saline). Data are the mean ± SEM of five dogs.    
*P < 0.05 compared with CLO + Vehicle (Dunnett’s test). †P < 0.05 compared with 
Sal + Vehicle (paired t-test). 
ChapterⅠ: Effects of mitemcinal on gastric emptying in normal and gastroparetic dogs 
15 
 
1.3.2.3 Motility 
Clonidine (0.03 mg/kg) administered subcutaneously immediately after a test meal inhibited 
postprandial antroduodenal contractions (Figures 1-7A, B). Oral administration of mitemcinal (1 
mg/kg) or cisapride (3 mg/kg) 15 min before feeding and clonidine immediately after feeding 
induced postprandial antroduodenal contractions in dogs administered clonidine (Figures 1-7 C, 
D), but the effects of mitemcinal were more prominent than those of cisapride. 
 
Figure 1-7  Typical tracings of contractile activity in dogs (A) without or (B) with 
administration of clonidine (0.03 mg/kg) immediately after feeding and in dogs 
given (C) mitemcinal (1 mg/kg) or (D) cisapride (3 mg/kg) 15 min prior to feeding. 
GA, gastric antrum; D, duodenum. 
 
1.3.3 Vagatomized dogs 
1.3.3.1 Gastric emptying 
Vagotomy significantly decreased all three indices of gastric emptying to approximately half the 
prevagotomy baseline values (Figure 1-8). Oral administration of mitemcinal (0.125, 0.25 or 0.5 
mg/kg) 15 min before feeding dose-dependently reversed these decreases, giving significant 
increases at doses of 0.25 and 0.5 mg/kg (Figure 1-8). Cisapride (3 mg/kg) administered in the 
same way caused the indices to recover to roughly their prevagotomy baseline values, but the 
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increases were not significant (Figure 1-8). These results indicate that mitemcinal dose-
dependently reversed the delay in gastric emptying induced by vagotomy, whereas cisapride 
caused only a non-significant tendency towards reversal. 
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Figure 1-8  Indices of gastric emptying before vagotomy (pre-VAG) and in 
vagotomized dogs given vehicle, mitemcinal or cisapride p.o. 15 min before a 
test meal. (A) Peak plasma paraceramol (AAP) concentration (Cmax), (B) plasma 
AAP concentration at 45 min (C45) and (C) area under the AAP concentration-time 
curve up to 60min after feeding (AUC0-60). Data are the mean ± SEM of nine dogs. 
*P < 0.05 compared with VAG + Vehicle (Dunnett’s test). †P < 0.05 compared with 
pre-VAG + Vehicle (paired t-test). 
 
1.3.3.2 Motility 
Vagotomy inhibited interdigestive and digestive antroduodenal contractions (Figure 1-9 A-D). 
Although spontaneous MMC still occurred in the gastric antrum and duodenum after vagotomy, 
the numbers and amplitudes of phase III contractions were lower and postprandial contractions 
were weak (Figure 1-9C, D). Oral administration of mitemcinal (0.25 mg/kg) or cisapride 
(3mg/kg) 15 min before feeding induced postprandial antroduodenal contractions in 
vagotomised dogs (Figure 1-9E, F), but the number and amplitude of the contractions were 
greater with mitemcinal than with cisapride. 
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Figure 1-9  Typical tracings of contractile activity (A, B) before and (C, D) after 
vagotomy and in vagotomized dogs given 0.25 mg/kg mitemcinal (E) or 3 mg/kg 
cisapride (F). GA, gastric antrum; D, duodenum. 
 
 
1.4 Discussion 
The results of the present study show that oral administration of mitemcinal increased the antral 
MI and significantly increased the indices of gastric emptying in a dose-dependent manner 
within a similar dose range in normal conscious dogs. Furthermore, in models of gastroparesis, 
mitemcinal reversed the decreases in antroduodenal contractions and the significant decreases in 
indices of gastric emptying induced by clonidine and vagotomy. These findings add to the 
existing evidence that mitemcinal is likely to be useful for the treatment of patients with 
gastroparesis. 
Because mitemcinal is a motilin agonist, it is considered that the stimulation of gastrointestinal 
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demonstrated that the stimulation of gastrointestinal motility in normal conscious dogs by 
mitemcinal was mediated by motilin receptors because the gastric contractions induced by 
mitemcinal were inhibited by a selective motilin receptor antagonist, namely GM-109 (Ozaki et 
al., 2007B). Because these gastric contractions were also inhibited by atropine, hexamethonium, 
ondansetron and dopamine, we suggested that mitemcinal may stimulate gastrointestinal 
motility in dogs by stimulating motilin receptors on 5-HT neurons in the vagal nerve or enteric 
nervous system, that the stimulation of 5-HT neurons may activate vagal efferent fibres via 5-
HT3 receptors and that the final mediator of the contractions in dogs may be acetylcholine 
(Ozaki et al., 2007B). The fact that mitemcinal increased the antral MI in a dose-dependent 
manner in normal conscious dogs in both the interdigestive and digestive states in the present 
study suggests that stimulation of gastrointestinal contractions by mitemcinal via motilin 
receptors was at least part of the mechanism by which it accelerated gastric emptying. 
In the present study, mitemcinal increased antroduodenal motility in both the digestive and the 
interdigestive states, as reported previously (Ozaki et al., 2007B), but higher doses of 
mitemcinal were required to produce this effect in the digestive state than in the interdigestive 
state. This finding is consistent with previous reports that stimulation of gastrointestinal motility 
by motilin agonists, such as motilin, erythromycin and erythromycin derivatives, is attenuated 
by food intake in conscious dogs (Ozaki et al., 2007B; Itoh, 1997; Shiba et al., 1995). The 
reason for this attenuation has not been identified clearly, but acidification in the stomach is a 
possible cause (Itoh et al., 1977). It is also possible that the gastric contents present in the 
digestive state delay the absorption of the motilin agonist. 
If stimulation of antroduodenal motility is the cause of acceleration of gastric emptying, the 
question arises as to why the lowest dose at which mitemcinal significantly accelerated normal 
gastric emptying (0.5 mg/kg) was lower than the lowest dose at which it increased antral MI in 
the digestive state (1 mg/kg). The reason may be the timing of administration. Mitemcinal was 
administered 15 min before a test meal in the gastric emptying experiment and 2 h after feeding 
in the motility experiment. If gastric contents delay its absorption, as speculated in the previous 
paragraph, mitemcinal must have been absorbed more rapidly in the 15 min before the test meal 
was eaten than at 2 h after feeding and, consequently, must have had a more pronounced effect 
on antroduodenal motility than it did when administered 2 h after feeding. Thus, the anomaly in 
effective doses mentioned above does not necessarily contradict the hypothesis that stimulation 
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of antroduodenal contractions by mitemcinal played an important role in accelerating gastric 
emptying.   
The fact that clonidine delayed gastric emptying and suppressed gastrointestinal motility in 
conscious dogs is consistent with previous studies that demonstrated that α2-adrenoceptor 
agonists such as clonidine (Tanaka et al., 1998), SC39585A (Gullikson et al., 1991) and 
UK14304 (Garcia-Garayoa et al., 1997) induce delayed gastric emptying in dogs by suppressing 
gastrointestinal motility and it is well known that activation of presynaptic α2-adrenoceptors 
causes inhibition of acetylcholine release from cholinergic nerves in the gastrointestinal tract 
and suppression of gastrointestinal motility.    
Truncal vagotomy decreased the number and amplitude of gastric contractions in the 
interdigestive and digestive states and delayed gastric emptying in conscious dogs. It is well 
known that the vagus nerve is the most important nerve for the regulation of gastrointestinal 
motility and it has been reported that although MMC cycles still occur in the interdigestive state 
in conscious dogs after truncal vagotomy, gastric contractions are greatly suppressed (Tanaka et 
al., 2001). It has also been reported that vagotomy causes delayed gastric emptying in dogs 
(Takeda et al., 1999; Carlson et al., 1991).  
Mitemcinal stimulated antroduodenal motility and significantly increased impaired gastric 
emptying at lower doses in vagotomised dogs than in clonidine-treated dogs. This may be 
because clonidine-treated dogs had more severe impairment of gastric emptying (Cmax, C45 and 
AUC0-60 of AAP decreased by approximately 70% after injection of clonidine compared with 
only approximately 50% after vagotomy). Alternatively, it may be because the efficacy of 
mitemcinal was affected by the different mechanisms by which clonidine and vagotomy inhibit 
gastrointestinal motility and gastric emptying. As stated above, we have suggested that 
mitemcinal may stimulate gastrointestinal contractions via acetylcholine release mediated by 
motilin receptors (Ozaki et al., 2007B). It is known that clonidine suppresses acetylcholine 
release from cholinergic nerves in the gastrointestinal tract (Tanaka et al., 1998; Gullikson et al., 
1991; Garcia-Garayoa et al., 1997), so mitemcinal and clonidine may compete functionally at 
the synapse of cholinergic neurons. Conversely, although truncal vagotomy above the 
diaphragm inhibits signalling from the central nervous system, the enteric nervous system, 
which may be one of the sites of mitemcinal activity, is likely to remain intact. 
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Oral administration of cisapride, which was the drug most widely used to treat patients with 
gastroparesis (Vandenplas et al., 2004), had no effect on gastric emptying in normal dogs in the 
present study and, although it increased motility in the interdigestive state, it had no effect on 
motility in the digestive state. In both gastroparetic models, cisapride caused some improvement 
in delayed gastric emptying, but its effects were slight and not significant and the dose-response 
curve in the clonidine-treated dogs was generally bell-shaped. There have been several studies 
on the effects of cisapride on gastric emptying in dogs, but the results have been mixed. In some 
studies, cisapride accelerated gastric emptying (Orihata et al., 1994; Gue et al., 1988), whereas 
in others it had no effect (Garcia-Garayoa et al., 1997; Sako et al., 2000). Tanaka et al. (1998) 
showed that 1 mg/kg cisapride increased gastric emptying, whereas 3 mg/kg decreased it, even 
though both doses increased motility. They suggested that cisapride may evoke a transient 
increase in antroduodenal resistance that makes the antroduodenal contractions it induces 
unsuitable for the acceleration of gastric emptying. The pronounced acceleration of gastric 
emptying by mitemcinal suggests that the antroduodenal contractions it induces are more 
coordinated than those induced by cisapride. 
In conclusion, mitemcinal stimulated antroduodenal motility and significantly accelerated 
gastric emptying in both normal and gastroparetic dogs in the present study, and its effects were 
more prominent than those of cisapride. Therefore, the results of the present study add to the 
evidence found in previous preclinical and clinical studies suggesting that mitemcinal may be 
useful for the treatment of patients with gastroparesis, so further clinical trials of mitemcinal are 
desirable. 
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2. Mitemcinal (GM-611), an orally active motilin receptor agonist, 
improves delayed gastric emptying in a canine model of 
diabetic gastroparesis 
2.1 Introduction 
Delayed gastric emptying is recognized as an important clinical complication of diabetes 
mellitus because it occurs in approximately 30-50% of patients with long-standing Type 1 and 
Type 2 diabetes (Horowitz et al., 2002) and causes upper gastrointestinal symptoms (discomfort, 
frequent vomiting, anorexia, etc.) that decrease patients’ quality of life (Talley, 1995). 
Autonomic neuropathy induced by prolonged hyperglycemia (Horowitz et al., 2002) is 
considered a major cause of delayed gastric emptying in patients with long-standing diabetes 
(Ziegler et al., 1996), although reversible delayed gastric emptying can be induced in diabetic 
patients by acute marked hyperglycemia (fasting plasma glucose [FPG] > ～300 mg/dL) alone 
(Fraser et al., 1990). Patients with clear symptomatic delayed gastric emptying are diagnosed as 
having diabetic gastroparesis (Talley, 1995). Several prokinetic drugs, such as metoclopramide, 
domperidone and cisapride, have been used to treat patients with diabetic gastroparesis 
(Vandenplas et al., 2004). Of these, metoclopramide and domperidone often give poor symptom 
response because their prokinetic effects are only moderate (Talley, 1995). In addition, they  
sometimes cause extrapyramidal reactions and hyperprolactinaemia (Tonini et al., 2004). 
Cisapride, a 5-hydroxytryptamine(5-HT)4 receptor agonist, has been demonstrated to effectively  
accelerate gastric emptying in normal subjects (Fraser et al., 1994) and to improve delayed 
gastric emptying in patients with gastroparesis (Vandenplas et al., 2004; Fraser et al., 1994). 
Although widely accepted as an effective treatment for gastroparesis, cisapride has been 
withdrawn from the market in many countries because it caused cardiovascular side-effects in 
humans (prolonged QT/QTc intervals and torsades de pointes) (Wysowski et al., 2001). 
Therefore, novel treatments for gastroparesis are needed to take the place of cisapride.  
Erythromycin, a macrolide antibiotic, has also been used to treat patients with gastroparesis 
(Vandenplas et al., 2004) because it stimulates gastrointestinal motility as a motilin receptor 
agonist (Peeters, 1993; Itoh, 1997). In clinical crossover studies, erythromycin caused 
significantly greater improvement of delayed gastric emptying and symptoms in patients with 
diabetic gastroparesis than metoclopramide (Snape Jr et al., 1982; Janssens et al., 1990), but the 
antibiotic activity of erythromycin makes its long-term use undesirable. Efforts to develop more 
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potent derivatives devoid of antibacterial properties have resulted in the development of a new 
class of prokinetics (Ōmura et al., 1987). However, a disadvantage shared by erythromycin and 
most erythromycin derivatives is that they rapidly degrade in the acidic environment of the 
stomach (Koga et al., 1994), making oral administration problematic. Mitemcinal (GM-611), a 
new erythromycin-derived motilin agonist, has the advantages of being orally active and devoid 
of antibacterial activity(Koga et al., 1994; Takanashi et al., 2007; Yogo et al., 2007; Ozaki et al., 
2007B). This agent has been shown to stimulate gastrointestinal motility and accelerate gastric 
empting better than erythromycin and other erythromycin derivatives, even after oral 
administration, in conscious dogs and monkeys (Ozaki et al., 2007B; Yogo et al., 2008). In 
clinical studies, mitemcinal has improved both delayed gastric emptying (McCallum et al., 
2007A) and symptoms in patients with diabetic gastroparesis, with minimal side-effects 
(McCallum et al., 2007B). 
Delayed gastric emptying has been observed in many established rodent diabetic models, such 
as streptozotocin (STZ)-induced diabetic rats and db/db mice (James et al., 2004; Liu et al., 
2004). However, these models are not useful for investigating of whether mitemcinal is effective 
on delayed gastric emptying induced by diabetes because the gastrointestinal tract of rodents is 
insensitive to motilin agonists (Strunz et al., 1975). There was a need for a new diabetic model 
in an animal whose gastrointestinal tract is sensitive to motilin agonists for the present study. 
The model also needed to be long lived, with stable moderate hyperglycemia, to maximize the 
chance of the animal developing delayed gastric emptying and to minimize the occurrence of 
reversible delayed gastric emptying due to marked acute hyperglycemia.  
Therefore, in the present study dogs were injected with a mixture of STZ and alloxan (ALX) to 
induce diabetes and those that developed stable moderate hyperglycemia (200-300 mg/dL) and 
did not need insulin therapy were selected and kept until they developed delayed gastric 
emptying.  After that, this canine model of diabetic gastroparesis was used to assess the effects 
of orally administered mitemcinal on delayed gastric emptying and to compare its effects with 
those of cisapride. Cisapride was chosen for comparison because the main need in the treatment 
of diabetic gastroparesis is for a safer replacement for cisapride. 
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2.2 Materials and methods 
2.2.1 Material 
Mitemcinal was synthesized in the organic laboratory of Chugai Pharmaceutical Co. Ltd 
(Shizuoka, Japan). Cisapride was extracted from Risamol® fine granules (Mitsubishi Pharma, 
Osaka, Japan). The structure and high quality (>99% pure by HPLC) of the extracted cisapride 
powder were confirmed by instrumental analyses ([1H]-nuclear magnetic resonance, mass 
spectroscopy and elemental analysis). Each drug was suspended in 3% gum arabic solution (the 
corresponding vehicle). Streptozotocin and ALX were purchased from Sigma Chemical (St. 
Louis, MO, USA); STZ was dissolved in 100 mmol/L citrate buffer (pH 4.5) and ALX was 
dissolved in distilled water. Both STZ and ALX were dissolved immediately prior to use 
because neither of these compounds is unstable in solution. 
 
2.2.2 Animals 
In total, 21 female beagle/CSK dogs (～10 kg; Chugai Research Institute for Medical Science, 
Shizuoka, Japan) were used. During the study, all dogs were housed individually in 
experimental cages, fed a dog diet (CD-5M; CLEA Japan, Tokyo, Japan) every morning and 
allowed free access to water. All animal procedures were conducted in accordance with Chugai 
Pharmaceutical’s Guide for the Care and Use of Laboratory Animals and all experimental 
protocols were approved by the Institutional Animal Care and Use Committee. 
 
2.2.3 Induction of diabetes in dogs 
After overnight fasting, 17 1-year-old dogs received a single intravenous injection containing a 
mixture of STZ (30 mg/kg) and ALX (50 mg/kg) to damage pancreatic β-cells (Black et al., 
1980). The FPG of these dogs was measured (Hitachi 7170 auto analyzer; Hitachi High 
Technologies, Tokyo, Japan) weekly up to 4 weeks post-STZ/ALX and then every 4 weeks until 
the end of the study. Bodyweight was also measured on the same schedule. Dogs that showed 
hyperglycemia (FPG > 200 mg/dL) during the first 8 weeks after STZ/ALX and in which the 
subsequent FPG never exceeded 300 mg/dL were used as ‘diabetic dogs’ in the present study. 
Because the hyperglycemia (FPG > 200 mg/dL) seen within the first 8 weeks after STZ/ALX 
was reversed before FPG increased again (see Results), the onset of diabetes was strictly defined 
as FPG > 200 mg/dL for 8 consecutive weeks (i.e. three consecutive sampling points at 4 week 
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intervals) after the increase in FPG again. The ‘normal dogs’ in the present study consisted of 
four control animals that did not receive STZ or ALX. The normal dogs were age-matched with 
the diabetic dogs to eliminate the possibility of age differences affecting the results. 
One and 5 years after the onset of diabetes, in diabetic and age-matched normal dogs, 
glycosylated hemoglobin (HbA1c) levels were measured (DCA2000+ analyzer; Bayer Medical, 
Tokyo, Japan), as were plasma aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT), as indices of hepatic function, and plasma creatinine, as an index of renal function 
(Hitachi 7170 auto-analyzer). At the same time, gastric emptying and motor nerve function were 
assessed in diabetic and normal dogs, as described below. 
 
2.2.4 Measurement of motor nerve conduction nelocity 
One and 5 years after the onset of diabetes, motor nerve conduction velocity (MNCV) was 
measured in the left hindlimb tibial nerve of diabetic and normal dogs under isoflurane general 
anesthesia (Forane®; Abbott Japan, Tokyo, Japan) according to conventional method (Lee et al., 
1970). Dogs were placed on a heated pad to maintain a constant rectal temperature of 38 ± 1ºC 
in a room kept at 25ºC. The tibial nerve area of each dog was exposed to a heating lamp and the 
skin temperature overlying the tibial nerve was kept stable because skin temperature can affect 
MNCV. The muscle action potentials evoked at two different sites of the tibial nerve (proximal 
and distal) by percutaneous two-point and supramaximal nerve stimulation (Neuropack Sigma 
EMG device; Nihon Kohden, Tokyo, Japan) were recorded. The MNCV was calculated as the 
ratio of the distance between the two stimulation sites (in mm) divided by the difference in the 
latencies (in msec) of the muscle action potentials at the two sites after nerve stimulation at both 
sites. 
 
2.2.5 Gastric emptying without prokinetics 
One and 5 years after the onset of diabetes in each diabetic dog, gastric emptying in the 
conscious state was assessed by the paracetamol method (Heading et al., 1973) and the results 
compared with those in age-matched normal dogs. To determine gastric emptying, after 
overnight fasting, each dog was fed 400 g of canned dog food (Pedigree Chum; 85 kcal/100 g; 
Master Foods, Tokyo, Japan) thoroughly mixed with 300 mg paracetamol (AAP; Wako Pure 
Chemical, Osaka, Japan) as a test meal. Blood samples were collected from a cephalic vein 
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every 15 min from 0 to 120 min, every 30 min from 120 to 180 min and then every 60 min from 
180 to 360 min after the test meal. Immediately after blood sampling, the plasma was separated 
and the plasma AAP concentration was measured by HPLC. As indices of gastric emptying, the 
following plasma AAP variables were calculated: peak plasma AAP concentration (Cmax), 
plasma AAP concentration at 60, 90 and 120 min (C60, C90 and C120, respectively), time to reach 
Cmax (Tmax) and the area under the AAP concentration-time curve up to 60, 90 and 120 min after 
feeding (AUC0-60, AUC0-90 and AUC0-120, respectively). 
 
2.2.6 Gastric emptying with prokinetics 
Five years after the onset of diabetes, diabetic and normal dogs were orally administered 0.5 
mL/kg of vehicle (3% gum arabic), a suspension of mitemcinal in vehicle (0.125, 0.25 or 0.5 
mg/kg) or a suspension of cisapride in vehicle (1, 3 or 10 mg/kg) via a rubber tube. Fifteen 
minutes later, as described above, dogs were given a AAP-spiked test meal, plasma AAP was 
measured and the plasma AAP variables were calculated. 
 
2.2.7 Histopathological examination 
At the end of the study, three diabetic dogs and three age-matched normal dogs were killed by 
exsanguination from the common carotid artery under deep pentobarbital anesthesia 
(Nembutal®; 35 mg/kg, i.v.; Abbott Laboratories, Chicago, IL, USA) and necropsied. For 
histopathological examination, the ventral and dorsal abdominal vagal nerves and the left tibial 
nerve were removed, gently stretched and fixed with 20% neutral buffered formalin. A piece of 
each nerve was embedded in paraffin (by the conventional method), thin sectioned and then 
stained with haematoxylin and eosin to enable observation of morphological changes and with 
Masson’s trichrome to enable observation of collagen fibers, in nerve fascicles under a light 
microscope. Immunohistochemical staining with mouse anti-neurofilament protein monoclonal 
antibody (DakoCytomation, Glostrup, Denmark) was also performed according to the labelled 
streptavidin-biotin method to enable observation of axons of myelinated and unmyelinated 
nerve fibers in the thin sections. 
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2.2.8 Statistical analysis 
All data are expressed as means ± SEM. Statistical analysis was performed by Student’s t-test to 
compare each parameter of diabetic and normal dogs. A paired t-test was used to compare each 
value after onset of diabetes in diabetic dogs with the pre-injection STZ/ALX baseline. 
Dunnett’s multiple comparison test was used to compare responses to mitemcinal or cisapride 
with responses to the corresponding vehicle. Dose-dependent effects of the drugs on the indices 
of gastric emptying were evaluated by the Jonckheere-Terpstra test. SAS version 8.2 (SAS 
Institute Japan, Tokyo, Japan) was used for the analyses. Differences were considered 
significant if P < 0.05. 
 
2.3 Results 
2.3.1 Selection of dogs with moderate hyperglycemia 
The 17 dogs injected with STZ/ALX were classified into the following three groups depending 
on the level and time-course of FPG during the first 8 weeks post-STZ/ALX: (i) a high-response 
group; (ii) a no response group; and (iii) a moderate-response group. 
There were eight dogs in the high-response group. Of these, five dogs died within 7 days after 
STZ/ALX, possibly because of ketoacidosis due to acute severe hyperglycemia (FPG > 600 
mg/dL) or hypoglycemia due to release of insulin from highly damaged pancreatic β-cells. In 
the other three dogs, the FPG concentrations remained above 300 mg/dL during the 8 week 
period and never fell below 300 mg/dL after that (e.g. FPG = 373 ± 21 mg/dL at 24 weeks after 
STZ/ALX; n=3). These three dogs were excluded from the study to avoid the influence of 
marked hyperglycemia on gastric emptying. 
There were five dogs in the no response group. These dogs did not show any marked increase in 
FPG at any sampling point during the first 8 weeks post-STZ/ALX (FPG = 112 ± 7 mg/dL at 8 
weeks after STZ/ALX; n=5), so were excluded from the study. 
In the remaining four dogs, FPG transiently increased to more than 200 mg/dL during the first 8 
weeks post-STZ/ALX. These four dogs were selected and used in the present study as the 
moderate-response group. 
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2.3.2 Onset of diabetes and associated changes in the moderate-response 
group 
After the first 8 weeks post-STZ/ALX, in each dog in the moderate-response group, FPG 
gradually decreased to less than 200 mg/dL (e.g. 165 ± 12 mg/dL at 12 weeks after STZ/ALX; 
n=4) and remained below 200 mg/dL for more than 1 year. After that, the FPG in each dog 
again increased gradually. In the final stage, stable moderate hyperglycemia (FPG > 200 mg/dL 
for 8 consecutive weeks) was achieved in all four dogs at 75 ± 12 weeks post-STZ/ALX (60, 60, 
64 and 112 weeks, respectively). The stable moderate hyperglycemia (FPG = 200-300 mg/dL) 
continued, without insulin treatment, to the end of the study (Figure 2-1A, Table 2-1). The 
HbA1c level was greater in diabetic dogs than in normal dogs 1 and 5 years after the onset of 
diabetes (Table 2-1). In diabetic dogs, bodyweight decreased rapidly after injection of STZ/ALX 
and was still significantly lower than in normal dogs 1 year after the onset of diabetes (P < 0.05). 
However, the bodyweight of diabetic dogs recovered gradually and was not significantly 
different from that of normal dogs 5 years after the onset of diabetes (Figure 2-1B, Table 2-1). 
The diabetic dogs tolerated STZ/ALX without marked increases in parameters of hepatic or 
renal function (AST, ALT, creatinine) at both 1 and 5 years after the onset of diabetes, although 
there was a slight and significant increase in creatinine (Table 2-1). 
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Figure 2-1  Time-course of (A) fasting plasma glucose and (B) bodyweight in age-
matched normal (○) and diabetic (●) dogs. The stable moderate hyperglycemia 
in diabetic dogs was induced by injection of streptozotocin and alloxan. Data are 
the mean ± SEM of four dogs. *P < 0.05 compared with normal dogs (Student’s t-
test). 
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2.3.3 Motor nerve function 
One and 5 years after the onset of diabetes, the MNCV of the tibial nerve was measured as an 
index of peripheral motor nerve function. The MNCV was significantly lower in diabetic dogs 
compared with normal dogs at both time points (Table 2-2). From 1 to 5 years after the onset of 
diabetes, the MNCV in diabetic dogs decreased, although not significantly, whereas the MNCV 
in normal dogs remained the same (Table 2-2). There was no significant difference in the 
temperature of the skin overlying the tibial nerve between diabetic and normal dogs 
immediately before the measurement of MNCV at either time point (Table 2-2). This indicates 
that the MNCV results in the present study were not affected by any difference in skin 
temperature. 
 
Table 2-2  Motor nerve conduction velocity of the tibial nerve in age-matched 
normal and diabetic dogs 
 
 MNCV  Skin temperature  
  (m/s)  (°C)  
1 year after the onset of diabetes 
 Normal dogs (no STZ or ALX) 70.7 ± 0.9 35.8 ± 0.2  
 Diabetic dogs (after STZ+ALX) 57.6 ± 0.4* 35.4 ± 0.2 
5 years after the onset of diabetes 
 Normal dogs (no STZ or ALX) 68.3 ± 1.8 36.1 ± 0.3  
 Diabetic dogs (after STZ+ALX) 50.1 ± 2.5* 35.9 ± 0.3  
Data are the mean ± SEM of four dogs. *P < 0.05 compared with normal dogs (Student’s t-test).  
MNCV, motor nerve conduction velocity.   
 
 
2.3.4 Gastric emptying 1 and 5 years after the onset of diabetes 
One year after the onset of diabetes, the time-course of the postprandial plasma AAP 
concentration and all indices of gastric emptying in diabetic and normal dogs were similar 
(Figure 2-2A, Table 2-3). Conversely, 5 years after the onset of diabetes, the postprandial 
ChapterⅡ: Effects of mitemcinal on delayed gastric emptying in diabetic dogs 
30 
plasma AAP concentration was lower in diabetic dogs at all plasma sampling times (Figure 2-2 
B) and the C90, C120 and AUC0-120 of plasma AAP (indices of gastric emptying) were also 
significantly lower (Table 2-3). Furthermore, the C60, C90, AUC0-90 and AUC0-120 of the AAP 
concentration in diabetic dogs at 5 years were significantly lower than in diabetic dogs at 1 year 
(Table 2-3). These results indicate that gastric emptying was significantly delayed in diabetic 
dogs at 5 years, but not 1 year, after the onset of diabetes. 
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Figure 2-2  Time-course of postprandial plasma paracetamol (AAP) in age-
matched normal (○) and diabetic (●) dogs (A) 1 and (B) 5 years after the onset 
of diabetes. Data are the mean ± SEM of four dogs. *P < 0.05 compared with 
normal dogs (Student’s t-test). 
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2.3.5 Gastric emptying with mitemcinal and cisapride 
When mitemcinal (0.125, 0.25 or 0.5 mg/kg) was administered orally 15 min before the test 
meal 5 years after the onset of diabetes, it dose-dependently reversed the decreased postprandial 
AAP concentration in diabetic dogs (Figure 2-3A) and, at the highest dose (0.5 mg/kg), the Cmax, 
C60, AUC0-90 and AUC0-120 of AAP were significant higher than in the vehicle group (Table 2-4). 
Cisapride (1, 3 or 10 mg/kg) administered in the same way showed a tendency to improve the 
decreased indices induced by long-standing diabetes, but the changes were not significant and 
the dose-response curve tended to be bell-shaped (Figure 2-3B, Table 2-4). These results 
indicate that mitemcinal overcame the delay in gastric emptying induced in dogs by long-
standing diabetes, whereas cisapride only caused a slight and non-dose-dependent tendency 
towards recovery. 
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Figure 2-3  Time-course of postprandial plasma paracetamol (AAP) in conscious 
dogs given (A) mitemcinal or (B) cisapride orally 15 min before a test meal 5 
years after the onset of diabetes. (○), vehicle (3% gum arabic); (●), 0.125 mg/kg 
mitemcinal (A) or 1 mg/kg cisapride (B); (▲), 0.25 mg/kg mitemcinal (A) or 3 
mg/kg cisapride (B); (■), 0.5 mg/kg mitemcinal (A) or 10 mg/kg cisapride (B); 
Data are the mean ± SEM of three or four dogs. *P < 0.05 compared with normal 
vehicle (Dunnett’s test). 
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2.3.6 Morphological changes of vagal and tibial nerves 
Immunohistochemically stained sections of the dorsal vagal and tibial nerves are shown in 
Figure 2-4. The images show that, in both nerves, there were fewer myelinated and 
unmyelinated nerve fibers and more interstitium in the diabetic dog than in the normal dog. 
There were no observable morphological differences between the dorsal and ventral vagal 
nerves. These morphological changes were observed in all of the diabetic dogs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4  Immunohistochemically stained sections of the dorsal vagal and tibial 
nerves. Each dot stained dark brown (neurofilament protein-positive area) shows 
the axon of a myelinated or unmyelinated nerve fiber. Bars, 20 μm. 
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2.4 Discussion 
The present study was performed in dogs injected with a mixture of STZ and ALX that 
developed diabetes and maintained a stable moderate hyperglycemia (FPG 200-300 mg/dL) 
without the need for insulin treatment. The results show that these dogs had developed delayed 
gastric emptying after 5 years of diabetes mellitus. They also show that oral mitemcinal (a novel, 
erythromycin-derived, motilin receptor agonist prokinetic agent) improved delayed gastric 
emptying in diabetic dogs. These findings add to the existing evidence that mitemcinal is likely 
to be useful for the treatment of patients with gastroparesis. 
Alloxan has often been used to induce diabetes in dogs, but a major drawback to its use is high 
mortality because diabetogenic doses of ALX (60-100 mg/kg) cause significant toxicity in 
organs such as the liver and kidney (Rerup, 1970). Simultaneous injection of STZ and ALX may 
have the advantage of inducing diabetes with a lower doses of both drugs (Black et al., 1980). In 
the present study, based on Black et al. (1980), diabetes was induced in dogs by a single 
injection of a mixture of STZ (30 mg/kg) and ALX (50 mg/kg) with the aim of inducing 
moderate hyperglycemia without causing lethal hepatic or renal damage. Different researchers 
have reported different degrees of hyperglycemia in dogs administered a combination of STZ 
and ALX; Gardiner et al. (2003) found that the conbination caused severe hyperglycemia 
requiring insulin treatment for long-term maintenance of stable hyperglycemia, whereas 
Anderson et al. (1993) reported that it caused moderate hyperglycemia (～200 mg/dL). In the 
present study, administration of an STZ/ALX mixture caused results similar reported in both 
these studies; among the 17 dogs injected with the combination, eight developed severe 
hyperglycemia, five did not respond and four, which were used in the present study, developed 
moderate hyperglycemia. Surprisingly, these four dogs showed stable hyperglycemia (FPG = 
200-300 mg/dL) without insulin treatment for a long period (5 years) without any severe 
impairment of hepatic or renal function. Therefore, this diabetic dog model may be suitable and 
convenient for the investigation of various complications that arise in patients with long-
standing diabetes. 
In the present study, gastric emptying was assessed by the paracetamol method; that is, by 
analyzing the time-course of plasma AAP concentration after a test meal containing AAP. This 
method gives a good picture of gastric emptying because AAP is not absorbed from the stomach, 
but is rapidly absorbed from the small intestine (Heading et al., 1973). The paracetamol method 
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has been widely used to assess gastric emptying in humans and in several animal species, 
including dogs (Yogo et al., 2007; Yogo et al., 2008; Heading et al., 1973; Sako et al., 2000; 
Ribel et al., 2002; Ozaki et al., 2008; Onoma et al., 2008; Kim et al., 2000; Willems et al., 
2001; Takeda et al., 2001). However, plasma AAP may be affected by liver or renal dysfunction 
because, after absorption from the small intestine, AAP is predominantly metabolized in the 
liver and excreted from the kidney (Forrest et al., 1982). Although there were slight but 
significant increases in creatinine 1 and 5 years after the onset of diabetes in all four diabetic 
dogs in the present study, hepatic and renal parameters remained within normal ranges 
established from historical data for healthy beagle dogs. Therfore, we consider that the 
paracetamol method was appropriate for assessing gastric emptying in the present study, even in 
the diabetic dogs. 
Although there was no significant change in the indices of gastric emptying in normal dogs at 1 
and 5 years, their postprandial plasma AAP-time curves had different shapes at these time points. 
The reason for this is thought to be the difference in the age of the dogs at these two time points. 
A similar phenomenon was observed in our study in minipigs (Ozaki et al., 2008). The 
possibility that age may affect gastric emptying is an important reason for using age-matched 
dogs as the control animals in the present study.  
It has been reported that marked acute hyperglycemia (> ～300 mg/dL) produced by glucose 
injection induced delayed gastric emptying in healthy volunteers and in Type 1 diabetic patients 
(Fraser et al., 1990; MacGregor et al., 1976). However, in the present study, delayed gastric 
emptying arose more than 1 year after the onset of diabetes, during a period of stable moderate 
hyperglycemia (FPG = 200-300 mg/dL), so the time of onset of delayed gastric emptying and 
the level of hyperglycemia at that time rule out acute reaction to hyperglycemia as the cause. It 
is therefore thought that the delayed gastric emptying seen in the present study arose gradually 
over a long period of moderate hyperglycemia by some disease mechanism other than simple 
acute reaction to hyperglycemia.  
Delayed gastric emptying appears to be more common in patients with autonomic neuropathy 
(Ziegler et al., 1996) and autonomic neuropathy is considered a major cause of diabetic 
gastroparesis (Undeland et al., 1996). In the present study, the MNCV of the tibial nerve was 
measured as an indicator of peripheral neuropathy. The MNCV of the tibial nerve was 
significantly lower at 1 year and tended to be even lower at 5 years after the onset of diabetes. 
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Although impairment of peripheral nerve function does not directly correlate with the existence 
of autonomic neuropathy, the progressive onset of peripheral neuropathy in these animals may 
give some support to the hypothesis that autonomic neuropathy was present at 5 years, when 
delayed gastric empting was observed. To clarify whether gastric autonomic neuropathy was, in 
fact, present at 5 years after the onset of the diabetes, histopathological examination of 
abdominal vagal nerves and the left tibial nerve was performed at the end of the study. 
Morphological changes, such as a decreased number of myelinated and unmyelinated nerve 
fibers and increased interstitial tissue, were observed in both the vagal and tibial nerves in 
diabetic dogs. These findings are consistent with previous reports of neural morphological 
changes in patients with diabetic gastroparesis (Guy et al., 1984; Britland et al., 1990). It seems 
that the intensity and extent of functional abnormalities caused by diabetic neuropathy parallel 
the degree and duration of hyperglycemia in diabetic patients (Clark Jr et al., 1995). In previous 
studied on dogs, Engerman et al. (Engerman et al., 1990; Kern et al., 2001) have also 
demonstrated that the duration of hyperglycemia greatly influences the development of diabetic 
complications. They have reported that poor glycemic control in diabetic dogs resulted in a 
progressive decline of the MNCV of the ulnar nerve that became statistically significant 4-5 
years after ALX injection (Engerman et al., 1990) and that the retinal hemorrhage was observed 
in dogs with diabetes for 5 years (Kern et al., 2001). Based on these results, the reason for the 
lack of delayed gastric emptying in diabetic dogs at 1 year after the onset of diabetes in the 
present study is considered to be that gastric diabetic autonomic neuropathy had not progressed 
sufficiently at 1 year to cause significant delay in gastric emptying.  
As mentioned above, there have been reports of severe structural abnormalities in the vagus 
nerve of diabetic gastroparesis patients (Guy et al., 1984; Britland et al., 1990). The findings of 
the present study support the view that vagal denervation may induce diabetic gastroparesis. In 
our previous study, a similar pattern of delayed gastric emptying was observed after truncal 
vagotomy in dogs (Onoma et al., 2008). Taken together, it is readily conceivable that abnormal 
abdominal vagal nerve function is an important cause of gastroparesis in diabetes. However, it 
has been reported that hormonal changes, a reduction in the number of intrinsic inhibitory 
neurons (essential for motor coordination) and a reduction in the number of pacemaker cells 
(e.g., interstitial cells of Cajal) are also involved in the etiology of diabetic gastroparesis 
(Camilleri, 2007). Further investigation would be desirable to determine whether gastric 
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autonomic neuropathy and the other mechanisms mentioned above correlate with delayed 
gastric emptying in dogs with diabetic gastroparesis. 
Oral mitemcinal accelerated gastric emptying in diabetic dogs in a dose-dependent manner and 
significantly increased some of the indices of gastric emptying at the highest dose tested (0.5 
mg/kg). Because previous studies showed that mitemcinal stimulated gastrointestinal 
contractions via motilin receptors (Ozaki et al., 2007B), as well as significantly increasing 
gastric motility and emptying in a dose-dependent manner within a similar dose range in 
conscious dogs with and without delayed gastric emptying (Onoma et al., 2008), it can be 
assumed that mitemcinal also accelerates gastric emptying in diabetic dogs by increasing 
gastrointestinal contractile activity via an action on motilin receptors. Oral administration of 
cisapride caused some improvement in delayed gastric emptying in the present study, but its 
effects were slight and not significant and the dose-response curve was somewhat bell-shaped. 
Results from earlier studies on the effects of cisapride on gastric emptying in dogs are somewhat 
conflicting. Although some studies found that cisapride significantly accelerated gastric 
emptying at doses of 0.16-1.25 mg/kg administered orally (Schuurkes, 1990), 0.3 mg/kg per h 
(Orihata et al., 1994) and 0.01 mg/kg per min i.v. infusion (Cowles et al., 2000), others found 
that cisapride had no significant effect at doses of 1 mg/kg administered into the duodenum 
(Sako et al., 2000), 1-10 mg/kg administered orally (Onoma et al., 2008) and 1 mg/kg, i.v. 
(Takeda et al., 2001). In another study, it was demonstrated that 1 mg/kg cisapride administered 
into the duodenum increased gastric emptying, but 3 mg/kg decreased it, even though both doses 
increased gastric motility (Tanaka et al., 1998). Similar results have been reported by Sako et al. 
(2000) and Onoma et al. (2008). In these studies, cisapride did not increase gastric emptying 
significantly even though it elicited gastric contractions at the same dose. Tanaka et al. (1998) 
suggested that cisapride may evoke a transient increase in antroduodenal resistance that makes 
the antroduodenal contractions it induces unsuitable for accelerating gastric emptying. Even in 
the study that showed significant enhancement of gastric emptying by cisapride, its effect was 
much weaker than those of erythromycin and its derivative (Cowles et al., 2000). Although the 
effect of mitemcinal, a new erythromycin-derived motilin agonist, on antroduodenal 
coordination in diabetic dogs remains to be elucidated, the fact that it causes pronounced 
enhancement of gastric emptying suggests that the antroduodenal contractions it does induce are 
more coordinated than those induced by cisapride. 
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Based on the results of the present study, we conclude that, like patients with diabetes mellitus, 
dogs in which long-standing diabetes has been induced by injection of a mixture of STZ/ALX 
show gastroparesis and associated morphological changes in abdominal vagal nerves. We also 
conclude that mitemcinal improves delayed gastric emptying in the diabetic dog model used in 
the present study and that its effects are more marked than those of cisapride. Taken together 
with the results from previous preclinical and clinical studies (Koga et al., 1994; Takanashi et 
al., 2007; Yogo et al., 2007; Ozaki et al., 2007B; Yogo et al., 2008; McCallum et al., 2007A; 
McCallum et al., 2007B; Ozaki et al., 2008; Onoma et al., 2008), the data suggest that 
mitemcinal may be useful for the treatment of patients with diabetic gastroparesis. 
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3. Effects of mitemcinal (GM-611), an orally active erythromycin-
derived prokinetic agent, on delayed gastric emptying and 
postprandial glucose in a new minipig model of diabetes 
3.1 Introduction 
In the last decade, delayed gastric emptying has become recognized as a clinically important and 
common complication of diabetes mellitus (occurring in approximately 30-50% of Type 1 and 
Type 2 diabetes patients) that causes upper gastrointestinal symptoms (discomfort, 
gastrointestinal symptoms, frequent vomiting, and emaciation) and decreases quality of life. 
Delayed gastric emptying also affects postprandial glucose profile because it impairs the 
delivery of nutrients to the small intestine, while, conversely, hyperglycemia tends to slow 
gastric emptying. In diabetic patients, there is evidence for both hyperglycemia and autonomic 
neuropathy as causes of delayed gastric emptying, and these two causes are linked by the 
likelihood that prolonged hyperglycemia causes autonomic neuropathy. Patients with clear 
symptomatic delayed gastric emptying are diagnosed as having diabetic gastroparesis. Novel 
treatments are needed for this disease (Horowitz et al., 2002). 
Gastric emptying can be accelerated by prokinetic agents such as erythromycin, an antibiotic 
that acts via motilin receptors to induce migrating motor-complex-like contractions in the upper 
gastrointestinal tract of dogs (Itoh et al., 1984), pigs (Mathis et al., 1995), and humans 
(Tomomasa et al., 1986). In clinical crossover studies, erythromycin caused significantly more 
improvement in delayed gastric emptying and symptoms in patients with diabetic gastroparesis 
than did metoclopramide (Janssens et al., 1990; Snape et al., 1982), but the antibiotic activity of 
erythromycin makes its long-term use in patients undesirable. Efforts to develop more potent 
derivatives devoid of antibacterial properties have given birth to a new class of prokinetics, the 
motilides (Ōmura et al., 1987), one of which is mitemcinal (GM-611), which is under clinical 
development. Mitemcinal has the advantages of being orally active and devoid of antibacterial 
activity (Koga et al., 1994), and has shown potent gastrointestinal-motility-stimulating activity 
via motilin receptors in rabbits (Takanashi et al., 2007), dogs (Ozaki et al., 2007A; Ozaki et al., 
2007B), and monkeys (Yogo et al., 2007). In clinical studies it has improved both delayed 
gastric emptying (Fang et al., 2004) and symptoms (McCallum et al., 2006) in patients with 
diabetic gastroparesis. Although there are many established animal models of diabetes, there are 
mainly in rats and mice. Since the gastrointestinal tracts of these animals are insensitive to 
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motilin and motilide, for the present study, we needed a new diabetic model in an animal whose 
gastrointestinal tract is sensitive to motilin and motilide. 
The domestic pig is very valuable for biomedical research because the anatomy and physiology 
of the cardiovascular and digestive systems of pigs and humans are similar (Swindle et al., 
1986; Miller et al., 1987; Tumbleson, 1986). As a diabetic model, streptozotocin (STZ)-induced 
diabetic pigs have been widely used to study endocrinology and metabolism in diabetes 
(Grussner et al., 1993; Ramsay et al., 2000; Koopmans et al., 2006), but their drawback is that 
their considerable size and weight make laboratory work difficult. This problem can be 
overcome by using minipigs. The Göttingen minipig is a standardized laboratory animal with a 
well-defined genetic background and health status, so we considered it an appropriate animal for 
use in this first study of mitemcinal’s effects on gastric emptying in an animal model of diabetes 
and the first study of the effects of mitemcinal on postprandial glucose. 
Delayed gastric emptying has been observed in STZ-induced diabetic rats and db/db mice (Liu 
et al., 2004; James et al., 2004), but very little information has been published about gastric 
emptying in diabetic minipigs or other large diabetic animals, or about metabolic or 
physiological abnormalities, particularly gastrointestinal disorders, in diabetic minipigs. 
Therefore, it was important to look for evidence of delayed gastric emptying in the model 
because the presence of delayed gastric emptying and a delayed-gastric-emptying-modified 
postprandial glucose profile would make diabetic minipigs potentially useful as a model of 
diabetic gastroparesis and would mean that the effects of mitemcinal on the model might have 
implications for the treatment of that disease. 
Diabetes had been induced by STZ in minipigs before (Larsen et al., 2002), but existing models 
were not suitable for studying complications (such as delayed gastric emptying) that may  
appear only after an extended period of hyperglycemia. To maximize the chance of creating a 
model of delayed gastric emptying in the present study, we needed a long-lived model with 
moderate hyperglycemia that would not need insulin therapy. To achieve this, we decided to try 
administering STZ to very young animals because we expected that there would be regeneration 
of islets of Langerhans in young minipigs after STZ treatment (such regeneration has since been 
confirmed; see Thyssen et al., 2006). The age of 5 weeks was chosen because minipigs cannot 
be weaned before that age. Our first task was to find a suitable dose of STZ for establishing 
diabetes in 5-week-old male Göttingen minipigs. 
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3.2 Materials and methods 
3.2.1 Animals 
Twenty-one male Göttingen minipigs were obtained from the Chugai Research Institute for 
Medical Science (Shizuoka, Japan), for use in the present study. During the study, all minipigs 
were housed individually in experimental cages, fed a minipig diet every morning (NS, 450 g; 
Nisseiken, Tokyo, Japan) and allowed free access to water. Before intravenous glucose 
tolerance tests and gastric emptying tests were performed, the minipigs were prepared by 
inserting an indwelling venous catheter (Terufusion® 14G; Terumo, Tokyo, Japan) into the sinus 
of the vena cava under isoflurane general anesthesia (Forane®; Abbott Japan, Tokyo, Japan). 
Blood samples were drawn from this catheter while the minipigs moved freely within their 
cages. 
To prepare the model, STZ (Sigma Chemical, St. Louis, MO, USA) was freshly dissolved in 
100 mmol/L citrate buffer (pH 4.5), and 100, 200, 300, or 400 mg/kg was administered 
intravenously to fifteen 5-week-old minipigs that had been fasted overnight. Weekly up to 4 
weeks post-STZ, the minipigs were weighed, and their fasting plasma glucose (FPG) was 
measured using a Hitachi 7170 auto analyzer (Hitachi High Technologies, Tokyo, Japan). Of the 
doses administered, the dose most appropriate for the present study was judged based on animal 
survival and hyperglycemia (FPG > 200 mg/dL) at 4 weeks post-STZ, and the minipigs that had 
received that dose were used as the ‘diabetic minipigs’ in the rest of the present study. The 
‘normal minipigs’ in the present study were control animals that did not receive STZ. These 
normal minipigs were age-matched with diabetic minipigs to eliminate the possibility of age 
difference affecting the results. The FPG concentration and bodyweight of normal and diabetic 
minipigs were measured regularly up to 87 weeks post-STZ.  
All animal procedures were conducted in accordance with Chugai Pharmaceutical’s Guide for 
the Care and Use of Laboratory Animals, and all experimental protocols were approved by the 
Institutional Animal Care and Use Committee. 
 
3.2.2 Pancreatic endocrine, hepatic, and renal functions 
To evaluate pancreatic endocrine function, an intravenous glucose tolerance test was performed 
in conscious minipigs at 51 weeks post-STZ, as follows. After overnight fasting, six diabetic 
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minipigs and three normal minipigs were administered an intravenous bolus injection of 0.5 
g/kg of 30w/v% glucose. Blood samples were collected 0, 3, 5, 7, 10, 15, 30, 45, 60, 90, and 120 
min after glucose injection, and plasma was immediately separated by centrifugation (5 min, 
12000 rpm, TMP-22; Hitachi Koki, Tokyo, Japan). Plasma insulin was measured using an 
enzyme-linked immunosorbent assay kit (Mercodia AB, Uppsala, Sweden), and plasma glucose 
was determined. The area under the insulin curve (AUC insulin) from 0 to 60 min was 
determined as an index of insulin production; the area under the glucose curve (AUC glucose) 
from 0 to 120 min was found; and the glucose disappearance rate (K) was calculated from the 
slope of the log plasma glucose curve between 1 and 30 min.  
Using a Hitachi 7170 autoanalyzer, plasma aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured as indices of hepatic function, and plasma creatinine 
and blood urea nitrogen (BUN) were measured as indices of renal function.. 
 
3.2.3 Gastric emptying without mitemcinal 
At 40 and 80 weeks post-STZ, gastric emptying in conscious minipigs was measured by the 
paracetamol method (Heading et al., 1973), as follows. After overnight fasting, six diabetic 
minipigs and six normal minipigs were fed 5 mL/kg OKUNOS-A liquid meal (14.2 g of 
carbohydrate, 5.1 g of protein, and 2.7 g of lipid; 104 kcal/100 mL; Forika Foods, Niigata, 
Japan) thoroughly mixed with 40 mg/kg bodyweight of paracetamol (AAP; Wako Pure 
Chemical, Osaka, Japan). Blood samples were drawn every 30 min up to 180 min after feeding, 
and plasma was immediately separated. Plasma AAP was measured by HPLC according to the 
method of Heading et al. (1973) with slight modification. 
 
3.2.4 Gastric emptying and postprandial glucose with mitemcinal 
At 80 weeks post-STZ, diabetic and normal minipigs were administered 0.5 mL/kg of either 
vehicle (3% gum arabic) or a suspension of mitemcinal (synthesized in the organic chemistry 
laboratory of Chugai Pharmaceutical, Shizuoka, Japan) in vehicle (5 mg/kg) orally via a rubber 
tube. Fifteen minutes later, the minipigs were given an AAP-spiked test meal, as above, and 
plasma AAP was determined, as above. Plasma glucose was also measured. 
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3.2.5 Statistical Analysis 
Statistical analysis was performed by Student’s t-test or paired t-test. P values were determined 
by Student’s t-test, unless otherwise specified, and were considered statistically significant if < 
0.05. All data are expressed as mean ± SEM. 
 
3.3 Results 
3.3.1 Induction of diabetes 
At 4 weeks postinjection, 300 mg/kg STZ was found to be suitable for establishing the desired 
minipig model because all animals were alive and had hyperglycemia (FPG > 200 mg/dL). In 
contrast, 100 and 200 mg/kg STZ did not induce hyperglycemia at 4 weeks post-STZ (FPG < 
140 mg/dL), whereas 400 mg/kg STZ induced marked hyperglycemia (FPG > 400 mg/dL) in 
two of four minipigs and caused death in the other two minipigs at 3 and 7 days after injection, 
possibly from hepatic or renal failure (Table 3-1). The six minipigs that had received 300 mg/kg 
STZ were therefore used as the ‘diabetic minipigs’ in the rest of the present study.  
In all six diabetic minipigs, FPG increased markedly to >300 mg/dL immediately after the 
injection of 300 mg/kg STZ, remained high for 6-7 weeks, and then gradually decreased. Stable 
moderate hyperglycemia (approximately 200 mg/dL) was maintained from 18 to 87 weeks post-
STZ (Figure 3-1A). Bodyweight gain was significantly lower in diabetic minipigs up to 22 
weeks post-STZ, but the difference in weight gain gradually decreased and was not significant 
from 24 to 87 weeks post-STZ (Figure 3-1B). 
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Figure 3-1  Time-course of (A) fasting plasma glucose and (B) bodyweight in age-
matched normal ( ○ ) and diabetic ( ● ) minipigs. The stable moderate 
hyperglycemia in diabetic minipigs was induced by injection of streptozotocin. 
Data are the mean ± SEM of three normal or six diabetic minipigs. The difference 
in fasting plasma glucose was significant at all sampling times. The difference in 
bodyweight gain was significant from 2 to 22 weeks, but not from 24 weeks. 
Significance was defined as P < 0.05, compared with normal minipigs (Student’s 
t-test).  
 
3.3.2 Pancreatic enzyme, hepatic, and renal functions 
At 51 weeks post-STZ, an intravenous glucose tolerance test in six diabetic minipigs and three 
normal minipigs revealed that, in the diabetic minipigs,  
－ Glycemic excursions were more marked (Figure 3-2A),  
－ AUC glucose was significantly higher (35,830 ± 1,369 vs. 15,163 ± 654 mg·min/dL; P<0.05) 
(Figure 3-2B),  
－ Glucose disappearance was significantly slower (K = －1.39 ± 0.08 vs. K = －3.71 ± 0.35; 
P<0.05), and  
－  Insulin production (AUC insulin) was significantly lower but did not fall below 
approximately 75% of normal (2183 ± 152 vs. 2921 ± 98 pg·min/mL; P<0.05) (Figure 3-2C). 
The minipigs tolerated the injection of 300 mg/kg STZ without a marked increase in hepatic or 
renal function parameters (AST, ALT, creatinine, and BUN) at 51 and 80 weeks post-STZ, 
although there was a slight but significant increase in ALT at 80 weeks post-STZ (Table 3-2). 
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Figure 3-2  (A) Plasma glucose, (B) the area under the glucose curve up to 120 
min and (C) the area under the insulin curve up to 60 min after an intravenous 
injection of glucose (0.5 g/kg at 0 min) in age-matched normal (○) and diabetic 
(●) minipigs. Data are the mean ± SEM of three normal or six diabetic minipigs. 
*P < 0.05 compared with normal minipigs (Student’s t-test). 
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3.3.3 Gastric emptying without mitemcinal 
Plasma AAP was lower in diabetic minipigs than in normal minipigs at all plasma sampling 
times at both 40 and 80 weeks post-STZ, but the only times it was significantly lower (P<0.05) 
were at 80 weeks post-STZ (150 and 180 min after feeding, Figure 3-3). Plasma AAP after an 
AAP-spiked meal is indicative of the rate of gastric emptying, so these results indicate that 
gastric emptying was significantly delayed in diabetic minipigs at 80 weeks, but not at 40 weeks, 
post-STZ. 
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Figure 3-3  Time-course of postprandial plasma paracetamol (AAP) in age-
matched normal (○) and diabetic (●) minipigs (A) 40 and (B) 80 weeks after 
300mg/kg streptozotocin injection. Data are the mean ± SEM of six minipigs. *P 
< 0.05 compared with normal minipigs (Student’s t-test). 
 
3.3.4 Gastric emptying and postprandial glucose with mitemcinal 
Mitemcinal significantly increased peak plasma AAP after feeding in both normal and diabetic 
minipigs (P<0.05; Figure 3-4), indicating that mitemcinal accelerated gastric emptying in both 
groups. The AAP time profiles after mitemcinal administration for normal and diabetic minipigs 
were quite similar (both peaking at approximately 60 min), which indicates that mitemcinal 
abolished delayed gastric emptying in diabetic minipigs.  
ChapterⅢ: Effects of mitemcinal on delayed gastric emptying in diabetic minipigs 
51 
Figure 3-5 shows postprandial glucose profiles for normal and diabetic minipigs after the 
administration of vehicle or mitemcinal at 80 weeks post-STZ. In the vehicle group, diabetic 
minipigs showed an exaggerated postprandial glucose excursion and prolonged elevation of 
plasma glucose compared to normal minipigs. In the mitemcinal group, normal minipigs and 
diabetic minipigs both showed clear postprandial glucose excursions that peaked at about the 
same time as plasma AAP, approximately 60 min after feeding. The postprandial glucose 
profiles of normal and diabetic minipigs were similar, but in diabetic minipigs, the plasma 
glucose peak was approximately twice as high, and plasma glucose fell more slowly thereafter, 
although faster than in diabetic minipigs administered vehicle (Figure 3-5). 
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Figure 3-4  Time-course of postprandial plasma paracetamol (AAP) in (A) age-
matched normal minipigs (○, vehicle; △, 5mg/kg mitemcinal) and (B) diabetic 
minipigs (● , vehicle; ▲ , 5 mg/kg mitemcinal) 80 weeks after 300mg/kg 
streptozotocin injection. Vehicle, 3% gum arabic. Data are the mean ± SEM of 
six minipigs. *P < 0.05 compared with vehicle (Student’s t-test). 
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Figure 3-5  Time-course of postprandial plasma glucose in (A) age-matched 
normal minipigs (○, vehicle; △, 5mg/kg mitemcinal) and (B) diabetic minipigs (●, 
vehicle; ▲ , 5 mg/kg mitemcinal) 80 weeks after 300mg/kg streptozotocin 
injection. Vehicle, 3% gum arabic. Data are the mean ± SEM of six minipigs. 
 
 
3.4 Discussion 
The present study provides evidence for the suitability of male minipigs induced with 300 
mg/kg STZ at 5 weeks of age for investigating some aspects of diabetes, including delayed 
gastric emptying and postprandial glucose profiles. It also shows that oral mitemcinal, a new 
prokinetic agent that is an erythromycin derivative, accelerates gastric emptying in normal and 
diabetic minipigs with delayed gastric emptying, and that mitemcinal alters the postprandial 
glucose profile in diabetic minipigs with delayed gastric emptying.  
Our results showed that the appropriate dose of STZ for the establishment of diabetes in 5-
week-old male Göttingen minipigs is 300 mg/kg, which is twice as high as the dose others have 
used to induce hyperglycemia in pigs (Grussner et al., 1993; Dufrane et al., 2006). One reason 
for this difference may be differences in strain and sex. But we consider the difference in age at 
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STZ injection (>12 weeks in earlier studies and 5 weeks in our study) to be a likely cause. Given 
that Dufrane et al. (2005) have found that the pancreases of young pigs have a higher proportion 
of small islets and isolated β-cells than those of adult pigs, it seems likely that isolated β-cells 
and small cell clusters are less sensitive to STZ.  
Our model showed stable moderate hyperglycemia for >80 weeks. Sufficient endogenous 
insulin production remained to enable the animals to live without exogenous insulin treatment 
and without major health problems. This is consistent with the finding of Dufrane et al. (2006) 
that no exogenous insulin is required to maintain stable hyperglycemia (approximately 200 
mg/dL) in STZ-induced diabetic pigs.  
In the present study, we assessed gastric emptying using the paracetamol method (i.e., by 
measuring  the time course of plasma AAP after a test meal containing AAP). This method 
gives a good picture of gastric emptying because AAP is not absorbed from the stomach but is 
absorbed rapidly from the small intestine (Heading et al., 1973; Kim et al., 2000). The 
paracetamol method has been widely used for the assessment of gastric emptying in humans and 
several animal species, including minipigs (Takeda et al., 1999; Ribel et al., 2002; Yogo et al., 
2007). 
After absorption from the small intestine, AAP is metabolized in the liver and excreted from the 
kidney, so liver or renal dysfunction may affect plasma AAP (Forrest et al., 1982). In the 
present study, although there was a slight but significant increase in ALT at 80 weeks post-STZ, 
the minipigs tolerated the injection of 300 mg/kg STZ without any marked increase in hepatic or 
renal functional parameters at 51 and 80 weeks post-STZ. We therefore consider the 
paracetamol method to be appropriate for assessing gastric emptying in the present study, even 
in diabetic animals. 
It is thought that the difference in the shape of plasma AAP time curves for normal minipigs at 
40 and 80 weeks was caused by the difference in bodyweight at these two time points. The 
whole of the present study was conducted during the minipigs’ growth stage, as shown in Figure 
3-1B, and Gregory et al. (1990) have found that the gastric emptying rate changes as 
bodyweight increases during the growth stage in domestic pigs. That is why it was also 
important to use age-matched minipigs as control animals in the present study. 
Plasma AAP increased up to 120min after a liquid test meal in both diabetic and normal 
minipigs at 80 weeks. The implied emptying rate may seem slow for a liquid meal, given that 
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liquid are emptied from the stomach more quickly than solids, but it should be noted that the test 
meal was a nutrient liquid, and nutrient liquids are emptied from the stomach more slowly than 
nonnutrient liquids because feedback inhibition is triggered by receptors distributed throughout 
the small intestine (Horowitz et al., 2002). 
Delayed gastric emptying was demonstrated at 80 weeks, but not at 40 weeks, post-STZ in the 
present study. It has been reported that acute marked hyperglycemia (more than approximately 
300 mg/dL) was caused by glucose-injection-induced delayed gastric emptying in diabetic rats 
(Chang et al., 1996), healthy volunteers, and Type 1 diabetic patients (Fraser et al., 1990; 
MacGregor et al., 1976). The hyperglycemia induced in diabetic minipigs in the present study 
was marked (>300 mg/dL) immediately after STZ injection, so gastric emptying may have been 
delayed by the marked hyperglycemia present during that early period. We only assessed gastric 
emptying at 40 and 80 weeks, by which time hyperglycemia had become stable and moderate 
(approximately 200mg/dL), so it was too low to cause delayed gastric emptying as an acute 
reaction to hyperglycemia. The delayed gastric emptying we detected arose between 40 and 80 
weeks while hyperglycemia was stable and moderate, which suggests that this delayed gastric 
emptying arose gradually over a long period of moderate hyperglycemia by some disease 
mechanism other than a simple acute reaction to hyperglycemia. 
Delayed gastric emptying appears to be more common in patients with autonomic neuropathy 
(Ziegler et al., 1996), and autonomic neuropathy is considered a major cause of diabetic 
gastroparesis (Hongo et al., 1993; Farrell et al., 1995; Undeland et al., 1996). Since, like the 
delayed gastric emptying we found at 80 weeks, diabetic neuropathy in human patients develops 
gradually over a long period of hyperglycemia (Clark et al., 1995), it seems reasonable to 
suggest that autonomic neuropathy and delayed gastric emptying may have developed in parallel 
with our model, and that the reason for the lack of delayed gastric emptying at 40 weeks may 
have been that neuropathy had not progressed sufficiently at that time to cause a significant 
delay in gastric emptying. Further investigation would be needed to demonstrate whether 
relevant autonomic neuropathy correlates with delayed gastric emptying in this model.  
The basis for concluding that gastric emptying was delayed in diabetic minipigs at 80 weeks is 
that plasma AAP was significantly lower in diabetic minipigs than in normal minipigs at 150 
and 180 min after the test meal at 80 waeeks. Although a siginificant difference in plasma AAP 
did not appear until 150 min after the test meal, plasma AAP was lower in diabetic minipigs 
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from 60min. Because half-life in the blood is approximately 3-4h, plasma AAP is largely an 
index of cumulative gastric emptying over time, so it can be expected that different rates of 
emptying (i.e., different rates of delivery of AAP into the duodenum for absorption) will cause 
increasingly marked differences in plasma AAP while faster emptying continues. The increasing 
difference in plasma AAP levels that finally became statistically significant at 150 min after the 
meal therefore indicates that there was a consistently slower rate of emptying in diabetic 
minipigs. 
Oral administration of 5 mg/kg of mitemcinal significantly accelerated gastric emptying in all 
minipigs, resulting in a very similar gastric emptying profile in normal and diabetic minipigs 
with delayed gastric emptying. This shows that mitemcinal can overcome delayed gastric 
emptying in diabetic minipigs. Since mitemcinal has shown potent prokinetic activity via 
motilin receptors in rabbits (Takanashi et al., 2007), dogs (Ozaki et al., 2007A; Ozaki et al., 
2007B), and monkeys (Yogo et al., 2007), and erythromycin (the parent compound of 
mitemcinal), a motilin agonist, has shown prokinetic activity in pigs (Mathis et al, 1995), we 
consider it likely that the prokinetic activity of mitemcinal in minipigs is mediated by motilin 
receptors. 
The oral dose of mitemcinal used in the present study (5 mg/kg) was selected based on the 
results of the previous studies,as follows. Our previous reports have shown that the dose of oral 
mitemcinal that significantly accelerated gastric emptying were 0.25-1 mg/kg in conscious dogs 
and 8.1 mg/kg in conscious monkeys (Koga et al., 2002). Given that, in dogs and monkeys, the 
potency of oral mitemcinal is 3-10 times that of oral erythromycin (unpublished data), and an 
oral erythromycin dose of >10 mg/kg is needed to produce siginificant prokinetic activity in 
pigs (Mathis et al., 1995), we considered that 5 mg/kg mitemcinal was within the suitable dose 
range for demonstrating prokinetic activity in minipigs.  
The safety and effectiveness of oral mitemcinal (10 mg, bid) as treatment for diabetic 
gastroparesis have also been investigated in humans, and mitemcinal has been shown to improve 
symptoms (McCallum et al., 2006) and delayed gastric emptying (Fang et al., 2004) in patients 
with diabetic gastroparesis. The fact that it also accelerates delayed gastric emptying in diabetic 
minipigs, the first animal model of diabetes in which it has been studied, adds to the evidence 
that mitemcinal is likely to be useful for the treatment of diabetic gastroparesis in human 
patients. 
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We consider the elevation and very slow decrease in postprandial glucose in diabetic minipigs 
administered vehicle to be the result of decreased insulin production, combined with a 
prolonged period of delivery of nutrients into the small intestine because of delayed gastric 
emptying. This is consistent with the finding that Type 1 diabetes patients with gastroparesis 
have postprandial glucose concentrations and insulin requirements that are different from those 
with normal gastric emptying (Ishii et al., 1994), and that delayed gastric emptying (common in 
longstanding diabetes) can cause unpredictable postprandial blood glucose levels because a 
mismatch between the timing of postprandial glucose excursion and the timing of the action of 
hyperglycemic drugs may induce unexpected hyperglycemia and/or hypoglycemia (Horowitz et 
al., 2002; Talley et al., 2001). The postprandial glucose profile in patients with diabetic 
gastroparesis will vary depending on how long emptying is delayed and the level of insulin 
production retained by the patient. This variability makes prediction and control of postprandial 
glucose very difficult.  
From 90 min after the meal, decrease in plasma glucose was much more rapid in the 
diabetes+mitemcinal group than in the diabetes+vehicle group. By accelerating gastric emptying, 
mitemcinal shortened the extended postprandial glucose excursion in diabetic minipigs. The 
postprandial glucose peak after mitemcinal occurred at about the same time in both normal and 
diabetic minipigs, although the resulting postprandial glucose peak was much higher in diabetic 
minipigs. This suggests that mitemcinal may be able to restore a more regular－and therefore 
more controllable－postprandial glucose profile in patients with diabetic gastroparesis. In other 
words, if mitemcinal makes the timing of the postprandial glucose peak in these patients more 
predictable, it should make it easier for the physician to select a hypoglycemic drug and 
administration timing so that its hypoglycemic effect coincides well with the glucose peak and 
that the risk of excessive hyperglycemia or hypoglycemia is avoided. On the other hand, it is 
likely that mitemcinal will make the postprandial glucose peak higher, as in diabetic minipigs, 
so this will have to be taken into account when selecting the dose of the hypoglycemic drug 
administered. 
In conclusion, the new diabetic minipig model showed suitability for investigating diabetes, 
gastric emptying, and plasma glucose excursions. Because delayed gastric emptying and 
irregular plasma glucose excursions are characteristic of diabetic gastroparesis, the accelerating 
and regulating effects of mitemcinal on this model add to the existing evidence that mitemcinal 
is likely to be useful for treating diabetic gastroparesis. 
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4. Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and 
cisapride on gastric emptying in conscious Rhesus monkeys 
4.1 Introduction 
Delayed gastric emptying is considered a major cause of symptoms in patients with 
gastrointestinal disorders such as functional dyspepsia and gastroparesis (Vandenplas, et al., 
2004; Talley, 1995). For example, it has been reported that gastric emptying of solids is 
significant delayed in up to 50% of patients with functional dyspepsia and in up to 75% of 
patients with Type 1 diabetes, and that upper gastrointestinal symptoms caused by delayed 
gastric emptying (e.g., discomfort, frequent vomiting, anorexia) decrease quality of life 
(Vandenplas, et al., 2004; Talley, 1995; Horowitz et al., 2002; Tack et al., 2001). A drug 
treatment for delayed gastric emptying has therefore been sought.  
Prokinetic drugs such as metoclopramide, domperidone, and cisapride (a 5-hydroxytryptamine4 
receptor agonist) were tried first (Vandenplas, et al., 2004; Talley, 1995), but metoclopramide 
and domperidone were sidelined because of poor symptomatic response (Talley, 1995) and 
adverse reactions such as extrapyramidal reactions and hyperprolactinemia (Tonini et al., 2004). 
On the other hand, cisapride effectively accelerated gastric emptying in normal subjects (Duan 
et al., 1995) and gastroparetic patients (Vandenplas, et al., 2004; Frase et al., 1994) and so 
became the treatment of choice for delayed gastric emptying. Cisapride has now been 
withdrawal from the market in many countries because of serious safety concerns (prolonged 
QT/QTc intervals and torsades de pointes in humans) (Wysowski et al., 2001), and no adequate 
replacement has yet been found. There were high hopes for erythromycin and its derivatives 
(Ōmura et al., 1987; Peeters, 1993), but the antibiotic activity of erythromycin rules out chronic 
use, and most derivatives cannot be administered in a convenient oral form that provides prompt, 
predictably timed drug absorption because their poor acid resistance makes them vulnerable to 
degradation in the stomach (Koga et al., 1994).  
However, there is a potent erythromycin derivative that has the crucial advantage of excellent 
acid resistance. That derivative is mitemcinal (GM-611). We are currently looking for evidence 
to suggest whether or not mitemcinal may have the potential to replace cisapride as the 
treatment of choice for delayed gastric emptying. So far, mitemcinal has shown potent and 
selective motilin receptor agonist activity and excellent acid-resistance in vitro (Koga et al., 
1994; Takanashi et al., 2007). In vivo, oral mitemcinal has stimulated gastrointestinal motility in 
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conscious dogs in a motilin-like manner (Ozaki et al., 2007B), and clinically, it has accelerated 
delayed gastric emptying and improved symptoms in patients with idiopathic and diabetic 
gastroparesis, while causing few adverse reactions (Fang et al., 2004; Kipnes et al., 2004; 
McCallum et al., 2006). Therefore, the evidence so far suggests that mitemcinal meets the 
requirements for a replacement for cisapride: good safety and efficacy against delayed gastric 
emptying when administered orally.  
Our earlier study in Rhesus monkeys established that, unlike other commonly used animals, the 
in vitro and in vivo responses of Rhesus monkeys to motilin and motilin agonists (including 
mitemcinal) are similar to those seen in humans (Yogo et al., 2007). Therefore, in the present 
study we administered oral mitemcinal and three comparators (erythromycin, EM-574 (Tsuzuki 
et al., 1989) and cisapride) in conscious Rhesus monkeys and assessed and compared the effects 
of these drugs on gastric emptying, with the aim of investigating whether the effects of 
mitemcinal in monkeys would give further support to the hypothesis that mitemcinal has the 
potential to take the place of cisapride. 
 
4.2 Materials and methods 
4.2.1 Materials  
Mitemcinal and EM-574 were synthesized according to the procedures in previous reports 
(Koga et al., 1994; Tsuzuki et al., 1989) in the organic chemistry laboratory of Chugai 
Pharmaceutical (Shizuoka, Japan), erythromycin was purchased from Sigma Aldrich Japan 
(Tokyo, Japan), and cisapride was extracted from Risamol® fine granules (Mitsubishi Pharma, 
Osaka, Japan). Each drug was suspended in 3% gum arabic to make the dosing solutions.  
The test meal was a liquid meal (Okunos® Liquid Food A; 14.5% carbohydrate, 5.1% protein, 
2.8% lipid, 240 J/mL; Forica Foods, Niigata, Japan) thoroughly mixed with paracetamol (AAP; 
Wako Pure Chemical, Osaka, Japan) to give a final AAP concentration of 40 mg/mL. 
 
4.2.2 Animals 
Six male Rhesus monkeys (approximately 5 kg; Chugai Research Institute for Medical Science, 
Shizuoka, Japan) were used. They were housed individually in experimental cages and fed 
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monkey diet (PS, 120 g/body, Oriental Yeast, Tokyo, Japan) and one piece of banana daily. To 
minimize the stress caused by the use of a nasogastric tube (6 Fr; Atom Medical, Tokyo, Japan) 
for drug and liquid meal administration, the monkeys were restrained in a monkey chair and 
acclimated to the insertion of a feeding tube into the stomach via the nose daily for the 7 days 
prior to each experiment. All animal procedures were conducted in accordance with Chugai 
Pharmaceutical’s Guide for the Care and Use of Laboratory Animals and all experimental 
protocols were approved by the Institutional Animal Care and Use Committee. 
 
4.2.3 Assessment of gastric emptying 
After overnight fasting, each monkey was restrained in a monkey chair and mitemcinal (1, 3 or 
10 µmol/kg), erythromycin (10, 30 or 100 µmol/kg), EM-574 (1, 3, 10 or 30 µmol/kg), cisapride 
(3, 10 or 30 µmol/kg) or the corresponding vehicle (3% gum arabic) was administered orally via 
a nasogastric feeding tube. About 15 min later, 10 mL/kg of liquid test meal was administered 
via the same tube. Using a heparinized syringe, a blood sample (0.5 mL) was collected from the 
cubital vein every 15 min (from 0 min to 90 min after the test meal) and then every 30 min 
(from 90 min to 180 min after the test meal). Plasma AAP concentration was measured by 
HPLC, and the peak plasma AAP concentration (Cmax), the plasma AAP concentration at 45 min 
after the test meal (C45) and the area under the plasma AAP concentration-time curve from 0 
min to 60 min after the test meal (AUC0-60) were calculated. A washout period of at least 1 week 
was allowed between experiments in the same monkey. 
 
4.2.4 Statistical analysis 
All data were expressed as mean ± SEM. Dunnett’s multiple comparison test was used to 
compare the Cmax, C45 and AUC0-60 of postprandial plasma AAP for each dose with those for the 
corresponding vehicle. P values less than 0.05 were considered statistically significant. 
Statistical analyses were carried out using SAS version 8.2 (SAS Institute Japan, Tokyo, Japan). 
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4.3 Results 
As qualitative representations of gastric emptying, time courses of postprandial plasma AAP 
concentration in conscious monkeys are shown in Figures 4-1 A-D. Increased peak plasma AAP 
and decreased time to peak plasma AAP give a visual indication of the acceleration of gastric 
emptying. When interpreting these graphs, it should be born in mind that the curves show the 
cumulative emptying of AAP into the small intestine, minus slow clearance from the blood. Oral 
mitemcinal and oral erythromycin both induced dose-dependent increases in peak plasma AAP 
and decreases in time to peak plasma AAP (Figures 4-1A, B), although a ten times higher dose 
of erythromycin was required to achieve a similar effect. Erythromycin induced a stronger 
response initially that then faded. EM-574 induced much less increase in plasma AAP, and the 
increases it did induce were limited to the early phase after the meal (Figure 4-1C). Cisapride 
also induced less increase in plasma AAP than mitemcinal and erythromycin, but the increases 
were more long-lasting than those induced by EM-574.  
As quantitative representations of gastric emptying, the Cmax, C45 and AUC0-60 of plasma AAP 
in each dose group are presented in Figure 4-2. Oral mitemcinal and oral erythromycin dose-
dependently increased all three indices, and the increases were significant at the highest doses 
(10 and 100 µmol/kg, respectively). Oral EM-574 caused only slight, non-significant increases 
that were similar at the two highest doses (10 and 30 µmol/kg), suggesting that a dose-response 
plateau was reached at 10 µmol/kg. Oral cisapride elicited a bell-shaped response, with a 
significant increase in only one index of gastric emptying, Cmax, at only one dose (the medium 
dose, 10 µmol/kg). The minimum effective doses were therefore 10 µmol/kg for mitemcinal and 
cisapride, and 100 µmol/kg for erythromycin. None of the doses of EM-574 were effective. 
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Figure 4-1  Time-course of postprandial plasma paracetamol (AAP) in conscious 
monkeys given (A) mitemcinal, (B) erythromycin, (C) EM-574 or (D) cisapride 
orally 15 min before a test meal. (A) ●, ○, △ and □; vehicle, 1, 3 and 10μmol/kg 
of mitemcinal, respectively. (B) ●, ○, △ and □; vehicle, 10, 30 and 100μmol/kg 
of erythromycin, respectively. (C) ●, ○, △, □ and ▲; vehicle, 1, 3, 10 and 30μ
mol/kg of EM-574, respectively. (D) ●, ○, △ and □; vehicle, 3, 10 and 30μmol/kg 
of cisapride, respectively. Vehicle, 3% gum arabic. Data are the mean ± SEM of 
six monkeys. 
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Figure 4-2  Indices of gastric emptying in conscious monkeys given mitemcinal, 
erythromycin, EM-574 or cisapride orally 15 min before a test meal. (A) Peak 
plasma paracetamol (AAP) concentration (Cmax), (B) plasma AAP concentration at 
45 min (C45) and (C) area under the AAP concentration-time curve up to 60 min 
after feeding (AUC0-60).Vehicle, 3% gum arabic. Data are the mean ± SEM of six 
monkeys. *P < 0.05 compared with the corresponding vehicle (Dunnett’s test) 
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4.4 Discussion 
So far, most preclinical studies of erythromycin and its derivatives, including mitemcinal, have 
been conducted in rabbits (in vitro) or dogs (in vivo) (Peeters, 1993; Takanashi et al., 2007; 
Ozaki et al., 2007B). However, there are important species differences between humans, rabbits 
and dogs in relation to response to motilin (Itoh, 1997). For example, in in vitro studies, rabbits 
showed a similar motilin response to humans, whereas dogs did not. Specifically, rabbit and 
human duodenal strips showed similar contractile responses to motilin (Strunz et al., 1976), 
whereas canine duodenal strips were not contracted by porcine motilin and were contracted by 
canine motilin only at nonphysiological high concentrations (Poitras et al., 1987). On the other 
hand, in in vivo studies it was dogs that showed a similar motilin response to humans, while 
rabbits did not. Specifically, the spontaneous migrating motor complex (MMC)-like 
contractions induced by motilin in the upper gastrointestinal tract migrated distally along the 
small intestine in dogs and humans (Itoh, 1997), but not in rabbits (Guerrero-Lindner et al., 
1996). Such species differences may make it difficult to predict the effects of erythromycin 
derivatives in humans based on results in dogs and rabbits. Results in an animal whose motilin 
response more closely matches the motilin response in humans are therefore desirable.  
We selected Rhesus monkeys for the present study because our earlier study showed that, unlike 
rabbits and dogs, the responses of Rhesus monkeys to motilin and motilin agonists were similar 
to those in humans, both in vitro and in vivo. Specifically, in vitro, motilin-specific binding in 
the smooth muscle layer of upper gastrointestinal tissues was demonstrated in monkeys, as in 
humans, and both motilin and mitemcinal contracted isolated duodenal strips via motilin 
receptors in monkeys, as in humans. Furthermore, in vivo, intravenously administered motilin 
and mitemcinal dose-dependently induced MMC-like gastrointestinal contractions and 
accelerated gastric emptying in monkeys, as in humans (Yogo et al., 2007). We therefore judged 
the Rhesus monkey to be a superior model of the human response to motilin receptor agonists 
such as mitemcinal.  
We investigated oral administration in the present study because, in addition to having good 
efficacy, any potential replacement for cisapride as the treatment of choice for treating delayed 
gastric emptying needs to be both (a) safe enough for long-term administration because diseases 
such as diabetic gastroparesis are chronic, and (b) potent as an oral formulation that enables the 
active ingredient to be emptied from the stomach as a liquid. Requirement (b) is essential, not 
only so that outpatients can easily take the drug before meals, but also to ensure predictably 
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timed drug delivery in patients in whom gastric emptying is delayed. The emptying of liquids is 
faster and more predictable than emptying of solids (including enteric coated tablets, etc.) 
(Horowitz et al., 2002). Erythromycin does not meet requirement (a) because its antibiotic 
activity makes it acceptable for acute administration only. Most erythromycin derivatives are 
not likely to meet requirement (b) because they have poor acid resistance (Koga et al., 1994; 
Takanashi et al., 2007). The present study demonstrated that mitemcinal, an erythromycin 
derivative with excellent acid resistance, is highly likely to meet requirement (b) because it had 
good potency when administered orally in monkeys. In contrast, a representative erythromycin 
derivative with poor acid resistance, EM-574, is unlikely to meet requirement (b) because it had 
poor potency when administered orally in monkeys.   
Cisapride and erythromycin were administered as benchmark comparators because their clinical 
efficacy against delayed gastric emptying is well established. EM-574 was administered as a 
comparator because it is as a representative erythromycin derivative with good potency when 
administered intravenously or duodenally (Inatomi et al., 1996; Sako et al., 2000), but poor 
acid-resistance (Takanashi et al., 2007). Prior to the present study, neither erythromycin, EM-
574 nor oral mitemcinal had been administered in monkeys, and the effects of mitemcinal on 
gastric emptying had not been compared with those of erythromycin or EM-574 in any animal.  
We assessed gastric emptying by the paracetamol method, that is, we qualitatively assessed 
gastric emptying by plotting the time course of plasma AAP after a test meal containing AAP, 
then we quantitatively assessed gastric emptying by calculating and testing the significance of 
change in the Cmax, C45 and AUC0-60 of the plasma AAP concentration. We used this method for 
the following reasons. Firstly, postprandial plasma AAP gives a good picture of gastric 
emptying because absorption of AAP does not occur in the stomach but occurs rapidly in the 
small intestine (Heading et al., 1973). Secondly, studies have shown that the Cmax, C45 and 
AUC0-60 of the plasma AAP concentration correlate well with radioisotope scintigraphy results 
for gastric emptying (Kim et al., 2000; Willems et al., 2001). Finally, the paracetamol method 
has been widely used to investigate gastric emptying in clinical studies (Kim et al., 2000).  
Oral mitemcinal accelerated gastric emptying in conscious monkeys in a dose-dependent 
manner and increased all three indices of gastric emptying significantly at the highest dose (10 
µmol/kg). Since our earlier study showed that motilin and mitemcinal stimulated gastrointestinal 
contractions via motilin receptors in monkeys both in vivo and in vitro, as in humans (Yogo et 
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al., 2007), it can be assumed that mitemcinal accelerated gastric emptying in monkeys in the 
present study because its activity as a motilin agonist increased gastrointestinal contractile 
activity. 
Oral erythromycin also accelerated gastric emptying in conscious monkeys in a dose-dependent 
manner and increased all three indices of gastric emptying significantly at the highest dose (100 
µmol/kg). Becuase oral mitemcinal was effective at 10 µmol/kg, oral mitemcinal is ten times 
more potent in monkeys than oral erythromycin. Erythromycin is unstable in acidic conditions 
such as occur in the stomach (Koga et al., 1994), but in marked contrast to EM-574, the effect of 
erythromycin was both sustained and dose-dependent. The sustained effect of erythromycin can 
be accounted for by the fact that, under acidic conditions, erythromycin first degrades to an even 
more potent motilin agonist intermediate (erythromycin enol ether) (Steinmetz et al., 2002). 
After that, the potent intermediate degrades to a low-potency product by irreversible ketalization 
between the 9-ketone and the 6- and 12-hydroxyl groups. The ultimate degradation of 
erythromycin to a low-potency product is probably the reason why, compared to mitemcinal 
(Figure 4-1A), the high dose of erythromycin administered induced a stronger response initially 
that then faded.  
Oral EM-574 had little effect on gastric emptying in conscious monkeys, and the responses it 
did induce were limited to the early phase after administration. Although the highest dose of 
EM-574 (30 µmol/kg) was three times higher than the effective dose of mitemcinal, the indices 
of gastric emptying plateaued before a significant response was achieved, suggesting that 
administration of even higher doses of EM-574 may not have induced a greater response. These 
results are similar to those found for gastrointestinal contractile activity in our earlier study, in 
which mitemcinal and EM-574 were orally and intravenously administered in conscious dogs 
(Ozaki et al., 2007B). In that study, oral mitemcinal had a stronger effect than oral EM-574, 
especially in the digestive state, and the relative potency of EM-574 was lower when 
administered orally than when administered intravenously. The reason for the lower relative 
potency of oral EM-574 in dogs in that study and/or the low potency of oral EM-574 in 
monkeys in the present study may be that EM-574 is not readily absorbed in the small intestine 
or that its potency is reduced by degradation in the stomach. In support of the latter hypothesis, 
it should be noted that in in vitro studies, EM-574 was rapidly degraded under acidic conditions, 
and that preincubation of the drug in acidic solutions greatly diminished the potency of EM-574 
but had no effect on the potency of mitemcinal (Takanashi et al., 2007). Given these in vitro 
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results and the fact that oral EM-574 did show some potency initially but then lost it, it is likely 
that at least part of the reason for the poor, short-lived potency of oral EM-574 in monkeys in 
the present study was its rapid degradation under the acidic conditions of the stomach.  
Oral cisapride induced a bell-shaped dose-response in the indices of gastric emptying in 
conscious monkeys, and a significant increase in only one index of gastric emptying, Cmax, at 
only one dose (the medium dose, 10 µmol/kg). A bell-shaped dose-response to cisapride has 
been reported in several other studies. For example, in common squirrel monkeys, oral cisapride 
improved delayed gastric emptying induced by cholecystokinin at 3 mg/kg (approximately 6 
µmol/kg) but had no effect at 10 mg/kg (approximately 21 µmol/kg) (Hatanala et al., 1996). 
Even more strikingly, Tanaka et al. (1998) found that although oral cisapride accelerated gastric 
emptying in dogs at 1 mg/kg, it actually delayed gastric emptying at 3 mg/kg, even though both 
doses of oral cisapride increased motility. Based on this startling result, they concluded that the 
antroduodenal contractions induced by cisapride may not be ideal for accelerating gastric 
emptying. In contrast, the more prominent accelerating effects of mitemcinal on gastric 
emptying in the present study suggest that mitemcinal may induce more coordinated 
gastroduodenal contractions that are more effective than those induced by cisapride. 
Becuase the present study was performed to look for evidence of the likely clinical efficacy of 
mitemcinal, it is important to consider the results of clinical studies of mitemcinal as well. 
However, before that, it should be acknowledged that potency at accelerating gastric emptying 
does not guarantee that a drug will ameliorate the symptoms of delayed gastric emptying. This 
was demonstrated in the case of another erythromycin derivative, ABT-229, which accelerated 
gastric emptying in healthy volunteers but did not improve the symptoms of patients with 
gastroparesis (Verhagen et al., 1997; Talley et al., 2000). Receptor desensitization may have 
been a factor in these results (Thielemans et al., 2005), but the importance of desensitization in 
the therapeutic failure of ABT-229 in patients with delayed gastric emptying is unclear. Becuase 
it is even less clear to what extent desensitization affects other motilin agonists, it is certainly 
too soon to conclude from the disappointing results for ABT-229 that no motilin agonist can 
succeed as a treatment agent for delayed gastric emptying.  
Turning to mitemcinal, clinical investigations (at 10 mg bid) have demonstrated that it can 
ameliorate symptoms as well as accelerate delayed gastric emptying in patients with diabetic 
gastroparesis, while causing few adverse reactions (Fang et al., 2004; Kipnes et al., 2004; 
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McCallum et al., 2006). To further explore its clinical safety, mitemcinal was subjected to a 
clinical ‘thorough QT/QTc study’ because QT/QTc interval prolongation has been induced by 
erythromycin and some erythromycin derivatives (Rubinstein, 2001). The results cleared 
mitemcinal from any suspicion that it might cause QT/QTc interval prolongation because it had 
no effect on ECG results, even at a supra-therapeutic dose (50 mg bid); whereas moxofloxacin 
(the positive control) clearly prolonged QT/QTc intervals (unpublished data). The results of 
these clinical studies, combined with those of the present study, suggest not only that 
mitemcinal is likely to be useful for the treatment of gastrointestinal disorders like gastroparesis, 
but also that it is likely to have minimal adverse effects. As stated above, safety is particularly 
important for a drug that will be used long-term to treat the symptoms of chronic conditions 
such as diabetic gastroparesis. 
In summary, oral mitemcinal demonstrated powerful effects on gastric emptying in Rhesus 
monkeys, suggesting that its excellent acid resistance gives it a clear advantage over other 
erythromycin derivatives such as EM-574. Because our earlier study showed that the effects of 
motilin and motilin agonists in monkeys and humans are very similar, these results suggest that 
oral mitemcinal is likely to have good efficacy in the treatment of delayed gastric emptying in 
humans. Mitemcinal is therefore likely to meet all the requirements for a replacement for 
cisapride, that is, good safety and efficacy against delayed gastric emptying when administered 
in a stomach-soluble oral format. Further clinical trials of mitemcinal for gastrointestinal 
disorders are therefore being planned 
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Concluding remarks 
Summary 
In order to investigate the possibility that mitemcinal, an orally active erythromycin-derived 
motilin receptor agonist, is likely to be useful for the treatment of patients with gastroparesis, 
the effects of mitemcinal on gastric emptying were tested in the present studies. 
 
At the first, in ChapterⅠ, effects of orally administered mitemcinal, an erythromycin-derived 
motilin agonist, on gastric emptying and antroduodenal motility were examined in conscious 
normal dogs and conscious dogs with experimentally delayed gastric emptying. For comparison, 
we also examined the effects of orally administered cisapride. In normal dogs, mitemcinal dose-
dependently accelerated gastric emptying, significantly increasing all three indices at doses of 
0.5 and 1 mg/kg; cisapride had no significant effects. Mitemcinal also dose-dependently 
stimulated antroduodenal motility in the interdigestive and digestive states. Cisapride, at 100-
fold the dose, produced similar effects in the interdigestive state, but mixed results in the 
digestive state. In dogs with delayed gastric emptying induced by subcutaneous clonidine (0.03 
mg/kg), mitemcinal dose-dependently improved delayed gastric emptying, significantly 
increasing two of three indices at a dose of 1 mg/kg. Cisapride caused non-significant increases 
in the indices of gastric emptying, with roughly bell-shaped dose-response curves. The highest 
dose of mitemcinal (1 mg/kg) also stimulated antroduodenal motility. In dogs with delayed 
gastric emptying induced by vagotomy, mitemcinal dose-dependently improved delayed gastric 
emptying, significantly increasing all three indices at doses of 0.25 and 0.5 mg/kg. Cisapride 
restored the indices to roughly prevagotomy levels, but none of the increases was significant. 
Mitemcinal at a dose of 0.25 mg/kg, also stimulated antroduodenal motility. Because delayed 
gastric emptying is the basic characteristic of gastroparesis, the fact that mitemcinal accelerated 
gastric emptying in dogs with normal and delayed gastric emptying much more robustly than 
cisapride adds to the evidence that mitemcinal is likely to be useful for the treatment of patients 
with gastroparesis. 
In ChapterⅡ, the effects of mitemcinal on delayed gastric emptying in a canine model of 
diabetic gastroparesis were evaluated and compared these effects with those of cisapride. 
Moderate hyperglycemia was induced by a single intravenous injection of a mixture of STZ (30 
mg/kg) and ALX (50 mg/kg). Dogs that maintained moderate hyperglycemia (fasting plasma 
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glucose 200-300 mg/dL) without insulin treatment were selected and gastric emptying in those 
dogs was determined by the paracetamol method. One year after the onset of diabetes, there was 
no difference in the gastric emptying of normal and diabetic dogs. However, after 5 years, the 
diabetic dogs showed delayed gastric emptying. The motor nerve conduction velocity of the 
tibial nerve was significantly lower in diabetic dogs compared with normal dogs at both time 
points. Histopathological examination at the end of the study showed that there were fewer 
nerve fibers in both dorsal vagal and tibial nerves of the diabetic dogs compared with normal 
dogs. The onset of delayed gastric emptying is thought to have occurred gradually, in parallel 
with abnormal autonomic nerve function induced by the long period of moderate hyperglycemia. 
Oral administration of mitemcinal dose-dependently accelerated delayed gastric emptying, 
significant at 0.5 mg/kg, in diabetic dogs, whereas cisapride had no significant effect. These 
results add to the existing evidence that mitemcinal is likely to be useful for treating diabetic 
gastroparesis. 
In ChapterⅢ, the aim of this study was to evaluate the suitability of a new minipig model for 
investigating aspects of diabetes such as delayed gastric emptying and glucose metabolism 
abnormalities, and to test the effects of mitemcinal on gastric emptying and postprandial glucose 
in normal and diabetic minipigs. Intravenous injection of 300 mg/kg STZ to 5-week-old 
minipigs induced moderate hyperglycemia (approxinately 200 mg/dL) for >80 weeks without 
insulin treatment. Decreased insulin production, increased AUC glucose, and slower glucose 
disappearance were demonstrated, and there was no severe inhibition of bodyweight gain, liver 
failure, or renal failure. Gastric emptying was significantly delayed in diabetic minipigs at 80 
weeks, but not at 40 weeks, post-STZ. Oral administration of mitemcinal (5 mg/kg) at 80 weeks 
accelerated gastric emptying and induced a similar postprandial glucose profile in normal and 
diabetic minipigs with delayed gastric emptying. Based on the results of this study, we conclude 
that STZ-induced diabetic minipigs induced with 300 mg/kg STZ at 5 weeks of age may be a 
useful model for studying diabetes and at least some of its complications, in particular irregular 
postprandial glucose profiles and delayed gastric emptying that are prominent problems in 
diabetic gastroparesis. Furthermore, we conclude that the effects of mitemcinal on delayed 
gastric emptying and postprandial glucose excursions in this diabetic model add to the existing 
evidence suggesting that mitemcinal may be useful for the treatment of diabetic gastroparesis. 
Finally, in ChapterⅣ, the effects of oral mitemcinal, erythromycin, EM-574 and cisapride on 
gastric emptying were assessed and compared in conscious Rhesus monkeys using the 
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paracetamol method. Mitemcinal and erythromycin induced significant, dose-dependent 
increases in indices of gastric emptying, but mitemcinal required a much lower dose for the 
same effect. Cisapride induced a bell-shaped dose response, and EM-574, a potent erythromycin 
derivative and originally developed as an enteric coated formulation, had little effect when it 
was given orally uncoated. Because our previous study showed that response to motilin is 
similar in Rhesus monkeys and humans, these results suggest that oral mitemcinal may be 
effective for the treatment of symptoms in human disorders related to delayed gastric emptying 
(e.g., functional dyspepsia and gastroparesis). Combined with the results of other studies, these 
results suggest that mitemcinal may be able to replace the withdrawn drug, cisapride, as the drug 
of choice for treating delayed gastric emptying. 
 
In conclusion, mitemcinal accelerated delayed gastric emptying in both experimentally-induced 
and diabetic gastroparetic animal models in a dose-dependent manner, and its effects were 
superior to those of cisapride. Furthermore, mitemcinal showed more potent effects on gastric 
emptying than erythromycin, EM-574 and cisapride in Rhesus monkeys after oral administration. 
In our previous study, it was demonstrated that the response of Rhesus monkeys to motilin and 
motilin agonists were quite similar to those in humans (Yogo et al., 2007). Taken together with 
results from the present studies, mitemcinal is likely to have more potent effects than other 
erythromycin derivatives and cisapride in the treatment of the patients with gastroparesis even 
after oral administration. 
 
Future prospects 
Currently prokinetic medications that stimulate gastric emptying are the mainstays of treatment 
for gastroparesis. The results of the present studies suggested that mitemcinal may be useful for 
the treatment of the patients with gastroparesis. The clinical development programs for 
mitemcinal have demonstrated that mitemcinal improved delayed gastric emptying (Fang et al., 
2004; Kipnes et al., 2004; McCallum et al., 2007A) and symptoms (McCallum et al., 2005; 
McCallum et al., 2007B) in patients with gastroparesis, while causing few adverse reactions. 
Although other prokinetic agents, including domperidone, cisapride, erythromycin and some 
erythromycin derivatives, have side effects to prolong the QTc interval on electrocardiographic 
testing (Bruera et al., 1986; Griffin, 2000; Ray et al., 2004; Rubinstein, 2001), a clinical 
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‘thorough QT/QTc study’ revealed that mitemcinal did not cause the QTc interval prolongation 
even at supra-therapeutic dose. Recently William (2008) and Poitras et al. (2008) introduced 
that mitemcinal is a newer oral motilin agonist which produced symptom benefits in patients 
with diabetic gastropathy in their review article respectively. We hope mitemcinal will be 
approved as a medicine for patients with gastroparesis as soon as possible. 
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